<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 1.1?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Hemasphere</journal-id><journal-id journal-id-type="iso-abbrev">Hemasphere</journal-id><journal-id journal-id-type="publisher-id">HS9</journal-id><journal-title-group><journal-title>HemaSphere</journal-title></journal-title-group><issn pub-type="epub">2572-9241</issn><publisher><publisher-name>Wolters Kluwer Health</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7410019</article-id><article-id pub-id-type="publisher-id">HemaSphere-2020-0153</article-id><article-id pub-id-type="doi">10.1097/HS9.0000000000000432</article-id><article-id pub-id-type="art-access-id">00010</article-id><article-categories><subj-group subj-group-type="heading"><subject>Guideline Article - Expert opinion</subject></subj-group><subj-group subj-group-type="hwp-journal-coll"><subject>002</subject></subj-group></article-categories><title-group><article-title>How We Manage Patients With Chronic Lymphocytic Leukemia During the SARS-CoV-2 Pandemic</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Rossi</surname><given-names>Davide</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Shadman</surname><given-names>Mazyar</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff4"><sup>4</sup></xref><xref ref-type="aff" rid="aff5"><sup>5</sup></xref></contrib><contrib contrib-type="author"><name><surname>Condoluci</surname><given-names>Adalgisa</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Brown</surname><given-names>Jennifer R.</given-names></name><xref ref-type="aff" rid="aff6"><sup>6</sup></xref></contrib><contrib contrib-type="author"><name><surname>Byrd</surname><given-names>John C.</given-names></name><xref ref-type="aff" rid="aff7"><sup>7</sup></xref></contrib><contrib contrib-type="author"><name><surname>Gaidano</surname><given-names>Gianluca</given-names></name><xref ref-type="aff" rid="aff8"><sup>8</sup></xref></contrib><contrib contrib-type="author"><name><surname>Hallek</surname><given-names>Michael</given-names></name><xref ref-type="aff" rid="aff9"><sup>9</sup></xref></contrib><contrib contrib-type="author"><name><surname>Hillmen</surname><given-names>Peter</given-names></name><xref ref-type="aff" rid="aff10"><sup>10</sup></xref><xref ref-type="aff" rid="aff11"><sup>11</sup></xref></contrib><contrib contrib-type="author"><name><surname>Mato</surname><given-names>Anthony</given-names></name><xref ref-type="aff" rid="aff12"><sup>12</sup></xref></contrib><contrib contrib-type="author"><name><surname>Montserrat</surname><given-names>Emili</given-names></name><xref ref-type="aff" rid="aff13"><sup>13</sup></xref><xref ref-type="aff" rid="aff14"><sup>14</sup></xref></contrib><contrib contrib-type="author"><name><surname>Ghia</surname><given-names>Paolo</given-names></name><xref ref-type="aff" rid="aff15"><sup>15</sup></xref><xref ref-type="aff" rid="aff16"><sup>16</sup></xref></contrib></contrib-group><aff id="aff1"><label>1</label>Division of Hematology, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland</aff><aff id="aff2"><label>2</label>Laboratory of Hematology, Institute of Oncology Research, Bellinzona, Switzerland</aff><aff id="aff3"><label>3</label>Division of Medical Oncology, Department of Medicine, University of Washington, Seattle, Washington, USA</aff><aff id="aff4"><label>4</label>Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA</aff><aff id="aff5"><label>5</label>Seattle Cancer Care Alliance, Seattle, Washington, USA</aff><aff id="aff6"><label>6</label>Chronic Lymphocytic Leukemia Center, Division of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, USA</aff><aff id="aff7"><label>7</label>The Ohio State University Comprehensive Cancer Center and Division of Hematology, Columbus, Ohio, USA</aff><aff id="aff8"><label>8</label>Division of Hematology, Department of Translational Medicine, University of Eastern Piedmont, Novara, Italy</aff><aff id="aff9"><label>9</label>Center of Integrated Oncology Cologne Bonn and German CLL Study Group, University of Cologne, Cologne, Germany</aff><aff id="aff10"><label>10</label>Haematological Malignancy Diagnostic Service, St. James's University Hospital, Leeds, United Kingdom</aff><aff id="aff11"><label>11</label>Section of Experimental Haematology, University of Leeds, Leeds, United Kingdom</aff><aff id="aff12"><label>12</label>Memorial Sloan Kettering Cancer Center, New York, New York, USA</aff><aff id="aff13"><label>13</label>Hospital Clinic, Barcelona, Spain</aff><aff id="aff14"><label>14</label>University of Barcelona, Barcelona, Spain</aff><aff id="aff15"><label>15</label>Division of Experimental Oncology, IRCCS Ospedale San Raffaele, Milan, Italy</aff><aff id="aff16"><label>16</label>Universit&#x000e0; Vita-Salute San Raffaele, Milan, Italy.</aff><author-notes><corresp>Correspondence: Davide Rossi and Paolo Ghia (<email>e-mails: davide.rossi@eoc.ch, ghia.paolo@hsr.it).</email></corresp></author-notes><pub-date pub-type="collection"><month>8</month><year>2020</year></pub-date><pub-date pub-type="epub"><day>30</day><month>7</month><year>2020</year></pub-date><volume>4</volume><issue>4</issue><elocation-id>e432</elocation-id><history><date date-type="received"><day>18</day><month>5</month><year>2020</year></date><date date-type="accepted"><day>2</day><month>6</month><year>2020</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2020 the Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the European Hematology Association.</copyright-statement><copyright-year>2020</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0"><license-p>This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0">http://creativecommons.org/licenses/by-nc-nd/4.0</ext-link></license-p></license></permissions><self-uri xlink:href="hs9-4-e432.pdf"/><abstract><title>Abstract</title><p>Infections are a major cause of morbidity and mortality in patients with chronic lymphocytic leukemia (CLL). These can be exacerbated by anti-leukemic treatments. In addition, the typical patients with CLL already have fragilities and background risk factors that apply to the general population for severe COVID-19. On these bases, patients with CLL may experience COVID-19 morbidity and mortality. Recurrent seasonal epidemics of SARS-CoV-2 are expected, and doctors taking care of patients with CLL must be prepared for the possibility of substantial resurgences of infection and adapt their approach to CLL management accordingly. In this Guideline Article, we aim at providing clinicians with a literature-informed expert opinion on the management of patients with CLL during SARS-CoV-2 epidemic.</p></abstract><custom-meta-group><custom-meta><meta-name>OPEN-ACCESS</meta-name><meta-value>TRUE</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>Many countries are following SARS-CoV-2 non-pharmaceutical mitigation policies, and, with the current data, it is impossible to determine how long such policies will be needed to establish sufficient herd immunity. Modeling suggests recurrent SARS-CoV-2 epidemic phases flaring up on the background of an endemic disease dictated by relaxation and reinstitution of the package of non-pharmaceutical interventions until an effective pharmacological treatment/prevention against COVID-19 will be available.<sup><xref rid="R1" ref-type="bibr">1</xref>,<xref rid="R2" ref-type="bibr">2</xref></sup></p><p>The rapidly expanding SARS-CoV-2 pandemic and its threats require a quick reaction prior to the availability of (eagerly awaited) evidence on how to manage patients with chronic lymphocytic leukemia (CLL) during this pandemic. Accordingly, this document was prepared by adapting existing guidance and scientific evidence to the new scenario imposed by the SARS-CoV-2 epidemics.</p><p>The aim of this document is to provide clinicians with a literature-informed expert opinion (Table <xref rid="T1" ref-type="table">1</xref>) developed through a bottom-up information processing and based on incoming data from publications and the clinics in SARS-CoV-2 infection and related infectious conditions including other oncological diseases.</p><table-wrap id="T1" orientation="portrait" position="float"><label>Table 1</label><caption><p>Summary of Recommendations About Management of Patients With CLL During the COVID-19 Pandemic.</p></caption><graphic xlink:href="hs9-4-e432-g001"/></table-wrap></sec><sec><title>Search strategy and selection criteria</title><p>A literature review was performed using PubMed to identify relevant English-language articles published through April 30, 2020 [search terms (coronavirus OR COVID OR SARS-CoV OR &#x02217;nCoV&#x02217;) AND (immunodeficiency OR leukemia OR cancer)]. Recommendations on the general themes of SARS-CoV-2, COVID-19 and CLL or cancer provided by ASH, ASCO, ASTCT, CDC, EBMT, EHA, ERIC, ESMO, iwCLL, NCCN, NIH, SSC, and WHO were also reviewed (last search on April 30th, 2020).</p></sec><sec><title>General considerations</title><sec sec-type="subjects"><title>We consider patients with CLL at increased risk of SARS-CoV-2 infection and COVID-19 morbidity and mortality due to their immune defect and fragility similar to patients with other malignancies</title><p>Whether the prevalence of COVID-19 in patients with cancer, including CLL, is higher than in sex- and age-matched normal population is uncertain.<sup><xref rid="R3" ref-type="bibr">3</xref>&#x02013;<xref rid="R5" ref-type="bibr">5</xref></sup> However, there is evidence that cancer conveys a poorer outcome in patients with COVID-19 infection.<sup><xref rid="R3" ref-type="bibr">3</xref>&#x02013;<xref rid="R10" ref-type="bibr">10</xref></sup> In addition, the risk of COVID-19 morbidity and mortality is thought to be higher in CLL due to the detrimental effect of comorbidities frequently occurring in patients with this leukemia, though this aspect has not been specifically addressed.</p><p>CLL can result in one or more of the following risk factors for infection: hypogammaglobulinemia, qualitative and quantitative B and T cell defects including impaired response to vaccination and CD4+ lymphopenia, innate immune dysfunction, and neutropenia among others.<sup><xref rid="R11" ref-type="bibr">11</xref></sup> These can be exacerbated by anti-leukemic treatments and are known risk factors for viral infections.<sup><xref rid="R12" ref-type="bibr">12</xref>,<xref rid="R13" ref-type="bibr">13</xref></sup> Thus, we can speculate that this existing immune suppression might also prevent or delay CLL patient's ability to react against the SARS-CoV-2 virus or to cope with COVID-19.</p><p>In addition, the typical patient with CLL may already have background risk factors for life-threatening COVID-19 that apply to the general population. Notably male gender, age &#x0003e;65 years, and medical conditions such as cardiovascular disease, diabetes, chronic respiratory disease, hypertension, other cancers, chronic kidney disease, and &#x0003e;2 underlying diseases are known risk factors of morbidity and mortality from COVID-19.<sup><xref rid="R14" ref-type="bibr">14</xref>&#x02013;<xref rid="R16" ref-type="bibr">16</xref></sup> Accordingly, around 70% of patients with CLL are male, 70% are older than 65 years, 25% harbor &#x0003e;2 comorbidities, 21% have hypertension, 13% cardiovascular disease, 26% diabetes, and 5% chronic respiratory disease.<sup><xref rid="R17" ref-type="bibr">17</xref>,<xref rid="R18" ref-type="bibr">18</xref></sup></p><p>Communication with patients can both mitigate emotional outcomes and improve adherence to public health, non-pharmaceutical interventions aiming at reducing the risk of infection.<sup><xref rid="R19" ref-type="bibr">19</xref></sup></p></sec><sec sec-type="cases"><title>We limit patients&#x02019; exposure to potential nosocomial SARS-CoV-2 infection by minimizing the number of visits, postponing in-hospital routine follow-up appointments, and substituting them with remote check-ins. Routine lab samples are often omitted in the absence of new or increasing symptoms and, in case they are needed, local/home collection is a viable option</title><p>There is solid evidence supporting that, in the absence of a vaccine, the sole effective prevention of SARS-CoV-2 infection and COVID-19 is public health, non-pharmaceutical interventions aimed at reducing contact rates in the population and thereby reducing transmission of the virus.<sup><xref rid="R20" ref-type="bibr">20</xref>&#x02013;<xref rid="R28" ref-type="bibr">28</xref></sup> Nosocomial spread of SARS-CoV-2 across patients and health-care professionals is a serious concern.<sup><xref rid="R29" ref-type="bibr">29</xref>&#x02013;<xref rid="R32" ref-type="bibr">32</xref></sup> The final goal should be to have COVID-19 free environments for safely and routinely taking care of patients with CLL, also during both endemic and future epidemic outbreaks, particularly in institutions with dedicated cancer centers.<sup><xref rid="R33" ref-type="bibr">33</xref></sup></p><p>Access to the hospital for investigations that are not iwCLL guideline recommended must be avoided to prevent nosocomial SARS-CoV-2 infection. Marrow aspirate and biopsy generally are not required for the diagnosis of CLL.<sup><xref rid="R34" ref-type="bibr">34</xref></sup> The staging of CLL does not use CT scans but relies on physical examination and blood counts.<sup><xref rid="R34" ref-type="bibr">34</xref></sup> The majority of relapses or progressions in CLL are detected by physical examination and blood counts, not by imaging studies.<sup><xref rid="R35" ref-type="bibr">35</xref></sup> For patients enrolled in clinical trials, the patient's safety remains a priority and it is better to avoid all unnecessary visits, CT scans and lab tests requested per protocol, following regulatory agencies and/or sponsor ad hoc guidelines. Only those exams that will have a direct impact on the clinical management of patients should be performed and in-hospital visits should be replaced with remote consultations.</p></sec></sec><sec sec-type="subjects"><title>Management of patients with CLL needing therapy during the pandemic</title><sec sec-type="subjects"><title>For patients in need of treatment, we recommend postponing initiation of therapy, if possible, until the epidemic trajectory is decreasing</title><p>CLL is a chronic disease that very rarely poses an imminent risk of death even when it is in advanced stage. The risk of death from COVID-19 in patients with CLL has not yet been established, making it difficult to balance the risks of SARS-CoV-2 infection and those of starting, deferring, or halting treatment on life expectancy. Nevertheless, under an epidemic scenario, we estimate the risks of community and nosocomial infection by SARS-CoV-2 and of complicated COVID-19 higher than the risk of delaying CLL treatment. Under an endemic scenario (ie, R&#x003c4; &#x0003c;1, where R&#x003c4; is the average number of secondary infections produced when one infected individual is introduced into a host population where everyone is susceptible, R&#x003c4; &#x0003e;1 indicates that outbreak will lead to an epidemic, and R&#x003c4; &#x0003c;1 that the outbreak will become extinct),<sup><xref rid="R36" ref-type="bibr">36</xref></sup> we estimate the benefit of a treatment known to prolong the survival of patients with CLL higher than the risks of community and nosocomial infection by SARS-CoV-2 and symptomatic COVID-19.</p><p>This reasoning is based on the following indirect evidence. First, in cancer patients, the COVID-19 case fatality rate is estimated to be 6% to 7%.<sup><xref rid="R6" ref-type="bibr">6</xref>&#x02013;<xref rid="R8" ref-type="bibr">8</xref>,<xref rid="R10" ref-type="bibr">10</xref>,<xref rid="R37" ref-type="bibr">37</xref>,<xref rid="R38" ref-type="bibr">38</xref></sup> Unadjusted statistics point to a higher mortality by COVID-19 among cancer patients than in the general population.<sup><xref rid="R4" ref-type="bibr">4</xref>,<xref rid="R5" ref-type="bibr">5</xref></sup> Likewise, in a retrospective study during the 2009 influenza A (H1N1) virus pandemic, cancer patients had a higher incidence of 30-day mortality (18%) compared with the general population.<sup><xref rid="R39" ref-type="bibr">39</xref></sup> Second, a pattern of decreasing risk of death was reported for the Middle East respiratory syndrome as the infection reproduction number declined toward a more endemic level (R&#x003c4; &#x0003c;1).<sup><xref rid="R40" ref-type="bibr">40</xref></sup> Third, the introduction of chemo(immuno)therapy and targeted agents in the treatment of CLL led to a 6% relative survival improvement and to a 10% decrease of deaths per 100-patient/year compared to palliative therapies used in the 1980s.<sup><xref rid="R41" ref-type="bibr">41</xref>,<xref rid="R42" ref-type="bibr">42</xref></sup></p><p>The decision about delivering treatment should be primarily influenced by the tempo of SARS-CoV-2 epidemiology, the local situation of the hospital and the potential therapeutic benefit of the anti-leukemic therapy. CLL rarely conveys the need for immediate, urgent therapy that cannot be postponed a few weeks while waiting for a decline of the outbreak and a safer delivery of the drugs. Therefore, during the rise and the peak of the SARS-CoV-2 epidemic, we strongly consider the possibility of delaying the start of a treatment even in advanced stage CLL. It is known that advanced stage CLL is seldom complicated by life-threatening end organ damage or profound, debilitating symptoms requiring immediate treatment. In addition, it is important to note that lymph node size and degree of cytopenia do not affect progression free survival of targeted treatment of CLL,<sup><xref rid="R43" ref-type="bibr">43</xref>&#x02013;<xref rid="R61" ref-type="bibr">61</xref></sup> and that cytopenias may remain stable over an extended period slightly below the suggested thresholds to initiate therapy.</p><p>Bulky disease, as per iwCLL guidelines, is defined as &#x0003e;10&#x0200a;cm lymph node size but this should not be axiomatically assumed to be synonymous with impending organ compression<sup><xref rid="R34" ref-type="bibr">34</xref></sup> and should be carefully evaluated on an individualized basis. In both treatment na&#x000ef;ve and relapsed CLL, bulky lymphadenopathy occurs in only 10% of patients.<sup><xref rid="R43" ref-type="bibr">43</xref>&#x02013;<xref rid="R61" ref-type="bibr">61</xref></sup></p><p>The iwCLL recommends starting therapy when the Hb level is &#x0003c;10&#x0200a;g/dL, as a proxy of lower quality of life and cardiovascular risk; in other conditions, symptomatic anemia rather than a defined cut-off is used to trigger intervention. Iron deficiency with or without anemia is a frequent complication in lymphoid malignancies and more in general in cancer, occurring in approximately 40% of cases and must be considered in the differential diagnosis of anemia.<sup><xref rid="R62" ref-type="bibr">62</xref>,<xref rid="R63" ref-type="bibr">63</xref></sup></p><p>Decreased hemoglobin for autoimmune hemolytic anemia can be managed with a course of corticosteroids and it is not an indication for anti-CLL treatment. Corticosteroids have the largest evidence of activity in CLL-related autoimmune hemolytic anemia and are the guidelines-recommended first line treatment.<sup><xref rid="R34" ref-type="bibr">34</xref></sup> It is not known whether corticosteroids increases the risk of SARS-CoV-2 infection or mitigates its severity.<sup><xref rid="R29" ref-type="bibr">29</xref>,<xref rid="R64" ref-type="bibr">64</xref>&#x02013;<xref rid="R70" ref-type="bibr">70</xref></sup> Clinical trials with novel agents excluded patients with uncontrolled autoimmune hemolytic anemia.<sup><xref rid="R43" ref-type="bibr">43</xref>&#x02013;<xref rid="R46" ref-type="bibr">46</xref>,<xref rid="R54" ref-type="bibr">54</xref>,<xref rid="R56" ref-type="bibr">56</xref>,<xref rid="R58" ref-type="bibr">58</xref>,<xref rid="R59" ref-type="bibr">59</xref></sup> However, treatment with BTK inhibitors facilitate withdrawal of ongoing immune suppressive agents in controlling hemolytic manifestations.<sup><xref rid="R71" ref-type="bibr">71</xref></sup></p><p>For platelets, according to the 2018 update of the iwCLL guidelines, a count &#x0003c;100 &#x000d7; 10<sup>9</sup>/l does not require immediate therapeutic intervention and can be tolerated, according to the bleeding risk, with regular monitoring.<sup><xref rid="R34" ref-type="bibr">34</xref></sup> One should also remember that thrombocytopenia may be a feature of the initial presentation of COVID-19.<sup><xref rid="R72" ref-type="bibr">72</xref>&#x02013;<xref rid="R74" ref-type="bibr">74</xref></sup> Immune thrombocytopenia can be effectively treated with corticosteroids but also with agents that are not immunosuppressive, such as intravenous immunoglobulin and oral thrombopoietic (TPO) agents.<sup><xref rid="R75" ref-type="bibr">75</xref></sup> Up to 78% of patients with CLL and immune thrombocytopenia respond to eltrombopag.<sup><xref rid="R76" ref-type="bibr">76</xref></sup> Potential increased risk of thrombosis, which is also a concern in COVID-19,<sup><xref rid="R77" ref-type="bibr">77</xref></sup> has been reported with the use of TPO agents and should be taken into account.<sup><xref rid="R75" ref-type="bibr">75</xref></sup> While prophylactic anticoagulation is recommended for hospitalized COVID-19 patients, its use in the outpatient setting for COVID-19 thrombosis prevention is not supported by prospective clinical trial data.</p><p>Disease-related symptoms (ie, extreme fatigue; unintentional weight loss &#x02265;10% within the previous 6 months; fever &#x0003e; 38.0&#x000b0;C for 2 or more weeks without evidence of infection; drenching night sweats for &#x02265;1 month without evidence of infection) or short lymphocyte doubling time (LDT) are very infrequently (&#x0223c;5%) the only reason to start therapy and we emphasize carefully excluding causes other than CLL.<sup><xref rid="R34" ref-type="bibr">34</xref>,<xref rid="R78" ref-type="bibr">78</xref></sup> Prolonged observation can sometimes show improvement of systemic symptoms or LDT.</p></sec><sec><title>When treatment cannot be further deferred, we use the systemic therapy that requires fewer clinic visits and/or is less immune suppressive</title><p>The rationale of the recommendation is to reduce the risk of nosocomial SARS-CoV-2 infection by reducing hospital visits and to avoid chemo(immuno)therapy, idelalisib plus rituximab and duvelisib, due to the concern about a higher risk of infection. Based on these considerations, we suggest ibrutinib or acalabrutinib and, for logistical reasons, venetoclax for patients not fitting for BTK inhibitors. We use BTK inhibitors as monotherapies instead of rituximab or obinutuzumab combinations and delay combining anti-CD20 monoclonal antibodies with venetoclax until later in the course of treatment when safer.</p><p>Ibrutinib, acalabrutinib, and venetoclax prolong progression-free and overall survival with lower risk of infections and similar/lower need for hospital care when compared to chemo(immuno)therapy.<sup><xref rid="R43" ref-type="bibr">43</xref>&#x02013;<xref rid="R46" ref-type="bibr">46</xref>,<xref rid="R54" ref-type="bibr">54</xref>,<xref rid="R56" ref-type="bibr">56</xref>,<xref rid="R58" ref-type="bibr">58</xref>,<xref rid="R59" ref-type="bibr">59</xref></sup> The percentage of opportunistic infections reported for ibrutinib is low (4.1%) and similar to that reported for venetoclax (3.1%).<sup><xref rid="R79" ref-type="bibr">79</xref>&#x02013;<xref rid="R82" ref-type="bibr">82</xref></sup> Compared to chemo(immuno)therapy, ibrutinib and acalabrutinib do not produce lymphopenia, a known risk factor for severe COVID-19.<sup><xref rid="R79" ref-type="bibr">79</xref>,<xref rid="R83" ref-type="bibr">83</xref>&#x02013;<xref rid="R85" ref-type="bibr">85</xref></sup> The incidence of any &#x02265;3 grade adverse events does not differ between ibrutinib (41%&#x02013;77%), acalabrutinib (50%), and venetoclax (78%), indicating that the frequency of unplanned visits for adverse event management is likely to be similar for the 3 drugs.<sup><xref rid="R43" ref-type="bibr">43</xref>&#x02013;<xref rid="R45" ref-type="bibr">45</xref>,<xref rid="R54" ref-type="bibr">54</xref>,<xref rid="R56" ref-type="bibr">56</xref>,<xref rid="R58" ref-type="bibr">58</xref></sup> Venetoclax may require additional unplanned visits for tumor lysis management during the ramp up phase.</p><p>Ibrutinib treatment requires few routine treatment visits and lab assessments.<sup><xref rid="R54" ref-type="bibr">54</xref></sup> It is associated with a low risk of neutropenia, and the immune reconstitution of T-cells, which in turns decreases the infection rate after the first 6 months of therapy.<sup><xref rid="R54" ref-type="bibr">54</xref>,<xref rid="R80" ref-type="bibr">80</xref>,<xref rid="R84" ref-type="bibr">84</xref>,<xref rid="R85" ref-type="bibr">85</xref></sup> BTK inhibitors are also undergoing investigation (NCT04346199) as an anti-inflammatory therapy in COVID-19, based on a few reports from uncontrolled clinical cases.<sup><xref rid="R86" ref-type="bibr">86</xref>,<xref rid="R87" ref-type="bibr">87</xref></sup> The disadvantage of ibrutinib treatment during SARS-CoV-2 outbreak is the continuous schedule not allowing treatment free intervals. However, if ibrutinib is discontinued because of an adverse event while CLL is in remission, the disease may continue being under control for a prolonged period of time before an alternative therapy is required.<sup><xref rid="R46" ref-type="bibr">46</xref>,<xref rid="R50" ref-type="bibr">50</xref>,<xref rid="R88" ref-type="bibr">88</xref>&#x02013;<xref rid="R90" ref-type="bibr">90</xref></sup></p><p>Venetoclax monotherapy preserves T-cells, and immunoglobulins, while transiently reducing the B-lymphocyte count. B-lymphocytes recover to normal levels within an average of 60 days from venetoclax discontinuation.<sup><xref rid="R83" ref-type="bibr">83</xref>,<xref rid="R91" ref-type="bibr">91</xref></sup> The disadvantage of venetoclax treatment is the need for frequent access to the hospital during the ramp-up phase to prevent tumor lysis syndrome (TLS).<sup><xref rid="R58" ref-type="bibr">58</xref></sup> In addition, venetoclax treatment has a relatively high risk of neutropenia during the first 3 months, though it does not translate into a high rate of infections and can be easily prevented through the use of G-CSF.<sup><xref rid="R79" ref-type="bibr">79</xref></sup> There is no evidence to support if, and to what extent, neutropenia is predictive of a negative outcome in SARS-CoV-2 infection.</p><p>Idelalisib and other approved PI3K inhibitors cause hyper-activation of the immune system resulting in significant autoimmune adverse events, including pneumonitis, and increase the risk of opportunistic infections, particularly when given as front-line therapy or in combination with anti-CD20 monoclonal antibodies.<sup><xref rid="R92" ref-type="bibr">92</xref>,<xref rid="R93" ref-type="bibr">93</xref></sup> In addition, in the relapsed setting, idelalisib plus rituximab treated patients have a shorter progression free survival and a higher drug discontinuation rate due to adverse events compared to acalabrutinib treated patients.<sup><xref rid="R59" ref-type="bibr">59</xref></sup></p><p>Treatment with rituximab or obinutuzumab produces a marked decrease of B-lymphocytes that may persist for a long time after treatment discontinuation.<sup><xref rid="R94" ref-type="bibr">94</xref></sup> Rituximab therapy may facilitate JC and hepatitis B viral reactivation.<sup><xref rid="R95" ref-type="bibr">95</xref>,<xref rid="R96" ref-type="bibr">96</xref></sup> Humoral immunity appears to facilitate COVID-19 recovery.<sup><xref rid="R97" ref-type="bibr">97</xref></sup></p></sec></sec><sec sec-type="subjects"><title>Management of patients with CLL undergoing anti-leukemic therapy during the pandemic</title><sec sec-type="subjects"><title>We test asymptomatic patients for SARS-CoV-2 infection by nasopharyngeal swab RT-PCR 72-24&#x0200a;hours before starting CLL therapy. During treatment, patients are questioned for clinical manifestations consistent with COVID-19, including atypical symptoms, over the phone or at the clinic's door</title><p>RT-PCR is the standard diagnostic test though its performance on nasopharyngeal swab for SARS-CoV-2 shows variable sensitivities ranging from 40% to 70%, but are consistently higher than RT-PCR of oropharyngeal swab.<sup><xref rid="R98" ref-type="bibr">98</xref>&#x02013;<xref rid="R102" ref-type="bibr">102</xref></sup> False negative RT-PCR tests have been reported in patients with CT findings of COVID-19 who were eventually tested positive on lower respiratory tract specimens or with serial upper respiratory tract samplings.<sup><xref rid="R103" ref-type="bibr">103</xref></sup></p><p>We monitor closely symptoms and keep a high suspicion for COVID-19 during treatment. Typical symptoms of COVID-19 are fever, myalgia, chills, coryza, cough, shortness of breath or sore throat. Gastrointestinal symptoms, as diarrhea, nausea, anosmia and ageusia can precede the development of fever and lower respiratory tract symptoms.<sup><xref rid="R104" ref-type="bibr">104</xref>&#x02013;<xref rid="R106" ref-type="bibr">106</xref></sup> The specificity of such symptoms toward COVID-19 diagnosis is decreased because they may overlap with common adverse events of CLL therapies. In addition, sensitivity of infection-control strategies only based on symptoms triage is limited and these policies are not sufficient to prevent transmission of SARS-CoV-2, with up 50% of SARS-CoV-2 infections detected in an asymptomatic or pre-symptomatic condition in a skilled nursing facility.<sup><xref rid="R107" ref-type="bibr">107</xref>,<xref rid="R108" ref-type="bibr">108</xref></sup></p><p>In patients developing symptoms consistent with COVID-19, we immediately isolate the patient and proceed to a comprehensive evaluation (SARS-CoV-2 RT-PCR on nasopharyngeal swabs, chest imaging studies, multiplex-nucleic antigen test including influenza, and other respiratory viruses and pathogens like pneumococci). We might offer imaging of the chest in patients without SARS-CoV-2 detected in the upper respiratory tract by RT-PCR but with clinical symptoms of lower respiratory infection.</p><p>Patients with CLL may have infectious diseases other than COVID-19, while COVID-19 symptoms are similar to other respiratory infections. Differential diagnoses must therefore include influenza and respiratory tract diseases. Indeed, even during the epidemic up to 50% of patients with fever and respiratory symptoms from the general population are positive for respiratory pathogens other than SARS-CoV-2, depending on the seasonal outbreaks and geographic location.<sup><xref rid="R9" ref-type="bibr">9</xref>,<xref rid="R109" ref-type="bibr">109</xref>&#x02013;<xref rid="R111" ref-type="bibr">111</xref></sup> In addition, approximately 10% to 50% of patients with COVID-19 have superinfections.<sup><xref rid="R9" ref-type="bibr">9</xref>,<xref rid="R111" ref-type="bibr">111</xref>&#x02013;<xref rid="R113" ref-type="bibr">113</xref></sup></p></sec></sec><sec sec-type="subjects"><title>Management of patients on treatment for CLL lacking evidence of COVID-19</title><sec sec-type="subjects"><title>We continue treatment with targeted agents in patients lacking COVID-19 symptoms as in normal circumstance with exception of anti-CD20 antibodies</title><p>We do not apply prophylactic interruption or dose reductions of ibrutinib, acalabrutinib or venetoclax based on the reasoning that once treatment has started, the dose intensity should be preserved to grant the maximum benefit. This is illustrated by the evidence that temporary ibrutinib dose interruptions associate with shorter progression free survival, suggesting that patients who are able to better adhere to treatment may derive more benefit.<sup><xref rid="R46" ref-type="bibr">46</xref>,<xref rid="R58" ref-type="bibr">58</xref>,<xref rid="R90" ref-type="bibr">90</xref>,<xref rid="R114" ref-type="bibr">114</xref>&#x02013;<xref rid="R119" ref-type="bibr">119</xref></sup></p></sec><sec sec-type="subjects"><title>In patients already receiving prophylactic immunoglobulin replacement therapy, the infusions will be used less frequently or replaced with s.c. formulations if available and patients can self-administer them at home</title><p>Physicians need to be aware that immunoglobulins are not specifically effective against SARS-CoV-2 because of a lack of specific antibodies within the product, but can help in preventing additional infections. Bacterial secondary infection can complicate viral infections, a situation well known in influenza, and emerging in COVID-19.<sup><xref rid="R120" ref-type="bibr">120</xref>,<xref rid="R121" ref-type="bibr">121</xref></sup> Immunoglobulin replacement therapy reduces the risk of major infection in patients with CLL and low serum IgG.<sup><xref rid="R122" ref-type="bibr">122</xref></sup> Subcutaneous formulations are non-inferior to intravenous formulations with the advantage of being self-administered by patients at home after a short training.<sup><xref rid="R123" ref-type="bibr">123</xref></sup> Given the higher risk of thromboembolic events with COVID-19, we recommend assessment of risks vs. benefits in each patient and close monitoring for thromboembolic symptoms.</p></sec><sec><title>We encourage to maintain the vaccination program in place at the treating institution including, in particular, against seasonal influenza and Streptococcus pneumoniae if not previously done</title><p>Due to the known susceptibility of patients with CLL to common infections, it is wise to protect them through vaccination including the common seasonal diseases such as influenza to limit diagnostic confusion in case of symptoms.<sup><xref rid="R121" ref-type="bibr">121</xref></sup> In some institutions, anti-meningococcal vaccination is also included.</p></sec></sec><sec sec-type="subjects"><title>Management of patients on treatment for CLL who receive a COVID-19 diagnosis</title><sec sec-type="subjects"><title>In patients on treatment for CLL, who receive a COVID-19 diagnosis, holding therapy until the recovery from infection is a prudent approach</title><p>Patients with CLL may be already at increased risk of developing life threatening COVID-19 for multiple reasons, including the underlying cancer, disease-related immune suppression, age, concomitant medical conditions and the immune suppressive effect of most CLL therapies.<sup><xref rid="R117" ref-type="bibr">117</xref>&#x02013;<xref rid="R119" ref-type="bibr">119</xref>,<xref rid="R124" ref-type="bibr">124</xref></sup> Thus, if the patient is receiving CLL therapy, its continuation should be carefully considered against the risk of drug-related immune suppression even in cases with mild COVID-19 symptoms. Occasional patients on BTK inhibitors, particularly those recently started and in whom the disease is not yet well controlled, may develop tumor flare with drug hold, which usually resolves rapidly with resumption of the inhibitor. However, most patients with well-controlled disease will remain stable during drug hold.</p><p>Despite mild symptoms at the onset of COVID-19, clinicians should be aware that patients at risk of life threatening COVID-19 could sometimes rapidly deteriorate, 1 to 2 weeks after illness onset.<sup><xref rid="R117" ref-type="bibr">117</xref>&#x02013;<xref rid="R119" ref-type="bibr">119</xref>,<xref rid="R124" ref-type="bibr">124</xref></sup> We counsel the COVID-19 team to closely monitor these patients with remote 24/24&#x0200a;hours home health care and real time rapid evaluation of complications or with hospitalization. Remdesivir is the sole approved pharmaceutical agent effective at treating severe COVID-19. Use of investigational therapies for treatment of patients with CLL and with COVID-19 should ideally be done in the context of randomized controlled trials.<sup><xref rid="R117" ref-type="bibr">117</xref>&#x02013;<xref rid="R119" ref-type="bibr">119</xref>,<xref rid="R124" ref-type="bibr">124</xref></sup></p></sec><sec sec-type="subjects"><title>We resume targeted agents if all the following conditions are met: (i) the patient is asymptomatic for at least 48&#x0200a;hours; (ii) at least 14 days have elapsed from symptoms start; (iii) at least two consecutive RT-PCR tests are negative on nasopharyngeal swab samples collected each approximately one week apart.</title><p>Beyond day 10 after symptom onset there is little residual risk of infectivity, based on cell culture of upper respiratory tract specimens, despite residual viral RNA shedding detected by RT-PCR.<sup><xref rid="R100" ref-type="bibr">100</xref></sup> The median range of SARS-CoV-2 viral shedding among patients with COVID-19 may indeed be up to 20 days from symptoms and may persist over longer periods in older persons, in those who received immunosuppressive therapy, and in those who had severe illness requiring hospitalization.<sup><xref rid="R98" ref-type="bibr">98</xref>&#x02013;<xref rid="R102" ref-type="bibr">102</xref>,<xref rid="R125" ref-type="bibr">125</xref>&#x02013;<xref rid="R130" ref-type="bibr">130</xref></sup></p><p>One single RT-PCR test on nasopharyngeal swab has up to 15% false negative results when performed at the time of COVID-19 recovery. It is likely that 2 negative RT-PCR tests on nasopharyngeal swab samples collected 24&#x0200a;hours apart may not be sufficient for viral clearance evaluation, since an average of 7&#x0200a;&#x000b1;&#x0200a;3 days between two tests is required to exclude an initial false negative assessment.</p><p>Appearance of specific IgG might also be informative, keeping in mind that the immunosuppression of patients with CLL in particular under anti-leukemic treatments may hamper a robust response. Seroconversion coincides with a slow but steady decline of sputum viral load and clinical recovery from COVID-19.</p><p>We would be prudent in resuming chemoimmunotherapy and consider a longer delay.</p></sec></sec><sec sec-type="conclusion"><title>Conclusion</title><p>If SARS-CoV-2 will transit from an epidemic to an endemic state, recurrent seasonal epidemics of SARS-CoV-2 are expected, and if immunity to SARS-CoV-2 wanes in the same manner as in related coronaviruses, recurrent wintertime outbreaks are likely to occur. The total incidence of SARS-CoV-2 through 2025 will depend crucially on the proportion of patients developing efficient immunity and its duration, as well as the availability of a vaccine and effective therapy. Doctors taking care of patients with CLL must be prepared for possible outbreaks of the infection and adapt the management of patients with CLL accordingly, by reintroducing strict preventive measures during SARS-CoV-2 reappearance, while relaxing them during the post-epidemic period until virus extinction. An expert opinion is the sole evidence that can be provided at the moment, given the lack of any specific data about COVID-19 in CLL. As understanding of SARS-CoV-2 and COVID-19 and the available information evolves, we expect the proposed approach will be modified in the future.</p><p>We hope that the comments and recommendations made in this paper are useful to the global medical community, patients with CLL and physicians looking after them. Also, that they serve as background for further refinement as our understanding of SARS-CoV-2 and COVID-19 infection unfolds, a process which requires a continued multidisciplinary and international collaboration.</p></sec><sec><title>Sources of Funding</title><p>DR received honoraria from Abbvie, AstraZeneca, Gilead, Janssen, Roche, Verastem, and research funding from Abbvie, Gilead, Janssen, Cellestia; MS received honoraria from Abbvie, Genentech, Astra Zeneca, Sound Biologics, Pharmacyclics, Verastem, ADC Therapeutics, Cellectar, Bristol Myers Squibb and Atara Biotherapeutics, and research funding from Mustang Bio, Celgene, Bristol Myers Squibb, Pharmacyclics, Gilead, Genentech, Abbvie, TG Therapeutics, Beigene, Astra Zeneca, Sunesis, Acerta Pharma, Beigene and Merck; JRB received honoraria from AbbVie, Acerta, AstraZeneca, BeiGene, Catapult Therapeutics, Dynamo Therapeutics, Genentech/Roche, Gilead, Juno/Celgene, Kite, Loxo, Novartis, Pfizer, Pharmacyclics, Sunesis, TG Therapeutics Janssen, Teva and Verastem, received research funding from Gilead, Loxo, Sun and Verastem, and is a member of the data safety monitoring board for Morphosys and Invectys; JCB received honoraria from Astra Zeneca, Acerta, Janssen Oncology, Pharmacyclics, and Verastem and research funding from Acerta, Pharmacyclics, and Celgene; GG received honoraria from Abbvie, Janssen, AstraZeneca, Sunesis. MH received honoraria from Roche, Gilead, Mundipharma, Janssen, Celgene, Pharmacyclics, Abbvie and research funding from Roche, Gilead, Mundipharma, Janssen, Celgene, Pharmacyclics, Abbvie; PH received honoraria from Acerta, Janssen, AbbVie; Pharmacyclics, Gilead and Roche; AM received honoraria from TG Therapeutics, Abbvie, Pharmacyclics, Johnson &#x00026; Johnson, Regeneron, Astra Zeneca, Genentech, LOXO, and Celgene, and research funding from TG Therapeutics, Abbvie, Pharmacyclics, Johnson &#x00026; Johnson, Regeneron, Genentech, LOXO, Portola, DTRM, and Acerta; PG received honoraria from AbbVie, Acerta/AstraZeneca, Adaptive, ArQule, BeiGene, CelGene/Juno, Dynamo, Gilead, Janssen, Sunesis, and research funding from AbbVie, Gilead, Janssen, Novartis, Sunesis.</p></sec></body><back><fn-group><fn fn-type="other"><p><bold>Citation:</bold> Rossi D, Shadman M, Condoluci A, Brown JR, Byrd JC, Gaidano G, Hallek M, Hillmen P, Mato A, Montserrat E, Ghia P. How we Manage Patients with Chronic Lymphocytic Leukemia During the SARS-CoV-2 Pandemic. <italic>HemaSphere</italic>, 2020;4:4(e432). <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1097/HS9.0000000000000432">http://dx.doi.org/10.1097/HS9.0000000000000432</ext-link></p></fn><fn fn-type="COI-statement"><p>The authors have no conflicts of interest to disclose.</p></fn></fn-group><ref-list><title>References</title><ref id="R1"><label>1.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leung</surname><given-names>K</given-names></name><name><surname>Wu</surname><given-names>JT</given-names></name><name><surname>Liu</surname><given-names>D</given-names></name><etal/></person-group>
<article-title>First-wave COVID-19 transmissibility and severity in China outside Hubei after control measures, and second-wave scenario planning: a modelling impact assessment</article-title>. <source><italic toggle="yes">Lancet.</italic></source>
<year>2020</year>;<volume>395</volume>:<fpage>1382</fpage>&#x02013;<lpage>1393</lpage>.<pub-id pub-id-type="pmid">32277878</pub-id></mixed-citation></ref><ref id="R2"><label>2.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kissler</surname><given-names>SM</given-names></name><name><surname>Tedijanto</surname><given-names>C</given-names></name><name><surname>Goldstein</surname><given-names>E</given-names></name><etal/></person-group>
<article-title>Projecting the transmission dynamics of SARS-CoV-2 through the postpandemic period</article-title>. <source><italic toggle="yes">Science.</italic></source>
<year>2020</year>;<volume>368</volume>:<fpage>860</fpage>&#x02013;<lpage>868</lpage>.<pub-id pub-id-type="pmid">32291278</pub-id></mixed-citation></ref><ref id="R3"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baumann</surname><given-names>T</given-names></name><name><surname>Delgado</surname><given-names>J</given-names></name><name><surname>Montserrat</surname><given-names>E</given-names></name></person-group>
<article-title>CLL and COVID-19 at the hospital Clinic of Barcelona: an interim report</article-title>. <source><italic toggle="yes">Leukemia.</italic></source>
<year>2020</year>;<volume>34</volume>:<fpage>1954</fpage>&#x02013;<lpage>1956</lpage>.<pub-id pub-id-type="pmid">32433507</pub-id></mixed-citation></ref><ref id="R4"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dai</surname><given-names>M</given-names></name><name><surname>Liu</surname><given-names>D</given-names></name><name><surname>Liu</surname><given-names>M</given-names></name><etal/></person-group>
<article-title>Patients with cancer appear more vulnerable to SARS-COV-2: a multi-center study during the COVID-19 outbreak</article-title>. <source><italic toggle="yes">Cancer Discov.</italic></source>
<year>2020</year>;<volume>10</volume>:<fpage>783</fpage>&#x02013;<lpage>791</lpage>.<pub-id pub-id-type="pmid">32345594</pub-id></mixed-citation></ref><ref id="R5"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mehta</surname><given-names>V</given-names></name><name><surname>Goel</surname><given-names>S</given-names></name><name><surname>Kabarriti</surname><given-names>R</given-names></name><etal/></person-group>
<article-title>Case Fatality Rate of Cancer Patients with COVID-19 in a New York Hospital System</article-title>. <source><italic toggle="yes">Cancer Discov.</italic></source>
<year>2020</year>;<volume>10</volume>:<fpage>935</fpage>&#x02013;<lpage>941</lpage>.<pub-id pub-id-type="pmid">32357994</pub-id></mixed-citation></ref><ref id="R6"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>J</given-names></name><name><surname>Ouyang</surname><given-names>W</given-names></name><name><surname>Chua</surname><given-names>MLK</given-names></name><etal/></person-group>
<article-title>SARS-CoV-2 Transmission in Patients With Cancer at a Tertiary Care Hospital in Wuhan, China</article-title>. <source><italic toggle="yes">JAMA Oncol.</italic></source>
<year>2020</year>;<comment>March 25. [Epub ahead of print]</comment>.</mixed-citation></ref><ref id="R7"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Desai</surname><given-names>A</given-names></name><name><surname>Sachdeva</surname><given-names>S</given-names></name><name><surname>Parekh</surname><given-names>T</given-names></name><etal/></person-group>
<article-title>COVID-19 and cancer: lessons from a pooled meta-analysis</article-title>. <source><italic toggle="yes">JCO Glob Oncol.</italic></source>
<year>2020</year>;<volume>6</volume>:<fpage>557</fpage>&#x02013;<lpage>559</lpage>.<pub-id pub-id-type="pmid">32250659</pub-id></mixed-citation></ref><ref id="R8"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liang</surname><given-names>W</given-names></name><name><surname>Guan</surname><given-names>W</given-names></name><name><surname>Chen</surname><given-names>R</given-names></name><etal/></person-group>
<article-title>Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China</article-title>. <source><italic toggle="yes">Lancet Oncol.</italic></source>
<year>2020</year>;<volume>21</volume>:<fpage>335</fpage>&#x02013;<lpage>337</lpage>.<pub-id pub-id-type="pmid">32066541</pub-id></mixed-citation></ref><ref id="R9"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>He</surname><given-names>W</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name><etal/></person-group>
<article-title>COVID-19 in persons with haematological cancers</article-title>. <source><italic toggle="yes">Leukemia.</italic></source>
<year>2020</year>;<volume>34</volume>:<fpage>1637</fpage>&#x02013;<lpage>1645</lpage>.<pub-id pub-id-type="pmid">32332856</pub-id></mixed-citation></ref><ref id="R10"><label>10.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Zhu</surname><given-names>F</given-names></name><name><surname>Xie</surname><given-names>L</given-names></name><etal/></person-group>
<article-title>Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China</article-title>. <source><italic toggle="yes">Ann Oncol.</italic></source>
<year>2020</year>;<volume>31</volume>:<fpage>894</fpage>&#x02013;<lpage>901</lpage>.<pub-id pub-id-type="pmid">32224151</pub-id></mixed-citation></ref><ref id="R11"><label>11.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Teh</surname><given-names>BW</given-names></name><name><surname>Tam</surname><given-names>CS</given-names></name><name><surname>Handunnetti</surname><given-names>S</given-names></name><etal/></person-group>
<article-title>Infections in patients with chronic lymphocytic leukaemia: mitigating risk in the era of targeted therapies</article-title>. <source><italic toggle="yes">Blood Rev.</italic></source>
<year>2018</year>;<volume>32</volume>:<fpage>499</fpage>&#x02013;<lpage>507</lpage>.<pub-id pub-id-type="pmid">29709246</pub-id></mixed-citation></ref><ref id="R12"><label>12.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>G</given-names></name><name><surname>Wu</surname><given-names>D</given-names></name><name><surname>Guo</surname><given-names>W</given-names></name><etal/></person-group>
<article-title>Clinical and immunological features of severe and moderate coronavirus disease 2019</article-title>. <source><italic toggle="yes">J Clin Invest.</italic></source>
<year>2020</year>;<volume>130</volume>:<fpage>2620</fpage>&#x02013;<lpage>2629</lpage>.<pub-id pub-id-type="pmid">32217835</pub-id></mixed-citation></ref><ref id="R13"><label>13.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Russell</surname><given-names>CD</given-names></name><name><surname>Millar</surname><given-names>JE</given-names></name><name><surname>Baillie</surname><given-names>JK</given-names></name></person-group>
<article-title>Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury</article-title>. <source><italic toggle="yes">Lancet.</italic></source>
<year>2020</year>;<volume>395</volume>:<fpage>473</fpage>&#x02013;<lpage>475</lpage>.<pub-id pub-id-type="pmid">32043983</pub-id></mixed-citation></ref><ref id="R14"><label>14.</label><mixed-citation publication-type="other">Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) Outbreak in China: summary of a report of 72,314 cases from the Chinese center for disease control and prevention. <italic>JAMA</italic>. 2020 February 24. [Epub ahead of print].</mixed-citation></ref><ref id="R15"><label>15.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Onder</surname><given-names>G</given-names></name><name><surname>Rezza</surname><given-names>G</given-names></name><name><surname>Brusaferro</surname><given-names>S</given-names></name></person-group>
<article-title>Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy</article-title>. <source><italic toggle="yes">JAMA.</italic></source>
<year>2020</year>;<comment>March 23. [Epub ahead of print]</comment>.</mixed-citation></ref><ref id="R16"><label>16.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>R</given-names></name><name><surname>Liang</surname><given-names>W</given-names></name><name><surname>Jiang</surname><given-names>M</given-names></name><etal/></person-group>
<article-title>Risk factors of fatal outcome in hospitalized subjects with coronavirus disease 2019 from a nationwide analysis in China</article-title>. <source><italic toggle="yes">Chest.</italic></source>
<year>2020</year>;<volume>158</volume>:<fpage>97</fpage>&#x02013;<lpage>105</lpage>.<pub-id pub-id-type="pmid">32304772</pub-id></mixed-citation></ref><ref id="R17"><label>17.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stauder</surname><given-names>R</given-names></name><name><surname>Eichhorst</surname><given-names>B</given-names></name><name><surname>Hamaker</surname><given-names>ME</given-names></name><etal/></person-group>
<article-title>Management of chronic lymphocytic leukemia (CLL) in the elderly: a position paper from an international Society of Geriatric Oncology (SIOG) Task Force</article-title>. <source><italic toggle="yes">Ann Oncol.</italic></source>
<year>2017</year>;<volume>28</volume>:<fpage>218</fpage>&#x02013;<lpage>227</lpage>.<pub-id pub-id-type="pmid">27803007</pub-id></mixed-citation></ref><ref id="R18"><label>18.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goede</surname><given-names>V</given-names></name><name><surname>Cramer</surname><given-names>P</given-names></name><name><surname>Busch</surname><given-names>R</given-names></name><etal/></person-group>
<article-title>Interactions between comorbidity and treatment of chronic lymphocytic leukemia: results of German Chronic Lymphocytic Leukemia Study Group trials</article-title>. <source><italic toggle="yes">Haematologica.</italic></source>
<year>2014</year>;<volume>99</volume>:<fpage>1095</fpage>&#x02013;<lpage>1100</lpage>.<pub-id pub-id-type="pmid">24584349</pub-id></mixed-citation></ref><ref id="R19"><label>19.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pfefferbaum</surname><given-names>B</given-names></name><name><surname>North</surname><given-names>CS</given-names></name></person-group>
<article-title>Mental Health and the Covid-19 Pandemic</article-title>. <source><italic toggle="yes">N Engl J Med.</italic></source>
<year>2020</year>;<comment>April 13. [Epub ahead of print]</comment>.</mixed-citation></ref><ref id="R20"><label>20.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cowling</surname><given-names>BJ</given-names></name><name><surname>Ali</surname><given-names>ST</given-names></name><name><surname>Ng</surname><given-names>TWY</given-names></name><etal/></person-group>
<article-title>Impact assessment of non-pharmaceutical interventions against coronavirus disease 2019 and influenza in Hong Kong: an observational study</article-title>. <source><italic toggle="yes">Lancet Public Health.</italic></source>
<year>2020</year>;<volume>5</volume>:<fpage>e279</fpage>&#x02013;<lpage>e288</lpage>.<pub-id pub-id-type="pmid">32311320</pub-id></mixed-citation></ref><ref id="R21"><label>21.</label><mixed-citation publication-type="other">World Health Organization. Country &#x00026; Technical Guidance - Coronavirus disease (COVID-19). 2020. <ext-link ext-link-type="uri" xlink:href="https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance">https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance</ext-link>. Accessed April 30, 2020.</mixed-citation></ref><ref id="R22"><label>22.</label><mixed-citation publication-type="other">Centers for Disease Control and Prevention. Infection Control Guidance for Healthcare Professionals about Coronavirus (COVID-19). 202. <ext-link ext-link-type="uri" xlink:href="https://www.cdc.gov/coronavirus/2019-ncov/hcp/infection-control.html">https://www.cdc.gov/coronavirus/2019-ncov/hcp/infection-control.html</ext-link>. Accessed April 30, 2020.</mixed-citation></ref><ref id="R23"><label>23.</label><mixed-citation publication-type="other">National Institutes of Health. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. 2020. <ext-link ext-link-type="uri" xlink:href="https://www.covid19treatmentguidelines.nih.gov/">https://www.covid19treatmentguidelines.nih.gov/</ext-link>. Accessed April 30, 2020.</mixed-citation></ref><ref id="R24"><label>24.</label><mixed-citation publication-type="other">European Centre for Disease Prevention and Control. COVID-19 2020. <ext-link ext-link-type="uri" xlink:href="https://www.ecdc.europa.eu/en/covid-19-pandemic">https://www.ecdc.europa.eu/en/covid-19-pandemic</ext-link>. Accessed April 30, 2020.</mixed-citation></ref><ref id="R25"><label>25.</label><mixed-citation publication-type="other">European Hematology Association. Frequently asked questions regarding SARS-CoV-2 in cancer patients: Recommendations for clinicians caring for patients with malignant diseases. 2020. <ext-link ext-link-type="uri" xlink:href="https://ehaweb.org/assets/Uploads/01-EHA-SWB-Infect-Manuscript-FAQ-COVID19-25032020.pdf">https://ehaweb.org/assets/Uploads/01-EHA-SWB-Infect-Manuscript-FAQ-COVID19-25032020.pdf</ext-link>. Accessed April 30, 2020.</mixed-citation></ref><ref id="R26"><label>26.</label><mixed-citation publication-type="other">American Society of Clinical Oncology. ASCO Coronavirus Resources. 2020. <ext-link ext-link-type="uri" xlink:href="https://www.asco.org/asco-coronavirus-information">https://www.asco.org/asco-coronavirus-information</ext-link>. Accessed April 30, 2020.</mixed-citation></ref><ref id="R27"><label>27.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hartley</surname><given-names>DM</given-names></name><name><surname>Perencevich</surname><given-names>EN</given-names></name></person-group>
<article-title>Public Health Interventions for COVID-19: Emerging Evidence and Implications for an Evolving Public Health Crisis</article-title>. <source><italic toggle="yes">JAMA.</italic></source>
<year>2020</year>;<comment>April 10. [Epub ahead of print]</comment>.</mixed-citation></ref><ref id="R28"><label>28.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pan</surname><given-names>A</given-names></name><name><surname>Liu</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>C</given-names></name><etal/></person-group>
<article-title>Association of Public Health Interventions With the Epidemiology of the COVID-19 Outbreak in Wuhan, China</article-title>. <source><italic toggle="yes">JAMA.</italic></source>
<year>2020</year>;<volume>323</volume>:<fpage>1</fpage>&#x02013;<lpage>9</lpage>.</mixed-citation></ref><ref id="R29"><label>29.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>D</given-names></name><name><surname>Hu</surname><given-names>B</given-names></name><name><surname>Hu</surname><given-names>C</given-names></name><etal/></person-group>
<article-title>Clinical characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China</article-title>. <source><italic toggle="yes">JAMA.</italic></source>
<year>2020</year>;<volume>323</volume>:<fpage>1061</fpage>&#x02013;<lpage>1069</lpage>.</mixed-citation></ref><ref id="R30"><label>30.</label><mixed-citation publication-type="journal"><collab>National University Cancer Institute of Singapore Workflow Team</collab><article-title>A Segregated-Team Model to Maintain Cancer Care During the COVID-19 Outbreak at an Academic Center in Singapore</article-title>. <source><italic toggle="yes">Ann Oncol.</italic></source>
<year>2020</year>;<volume>31</volume>:<fpage>840</fpage>&#x02013;<lpage>843</lpage>.<pub-id pub-id-type="pmid">32243893</pub-id></mixed-citation></ref><ref id="R31"><label>31.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ueda</surname><given-names>M</given-names></name><name><surname>Martins</surname><given-names>R</given-names></name><name><surname>Hendrie</surname><given-names>PC</given-names></name><etal/></person-group>
<article-title>Managing Cancer Care During the COVID-19 Pandemic: Agility and Collaboration Toward a Common Goal</article-title>. <source><italic toggle="yes">J Natl Compr Canc Netw.</italic></source>
<year>2020</year>;<fpage>1</fpage>&#x02013;<lpage>4</lpage>.</mixed-citation></ref><ref id="R32"><label>32.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>He</surname><given-names>X</given-names></name><name><surname>Lau</surname><given-names>EHY</given-names></name><name><surname>Wu</surname><given-names>P</given-names></name><etal/></person-group>
<article-title>Temporal dynamics in viral shedding and transmissibility of COVID-19</article-title>. <source><italic toggle="yes">Nat Med.</italic></source>
<year>2020</year>;<volume>26</volume>:<fpage>672</fpage>&#x02013;<lpage>675</lpage>.<pub-id pub-id-type="pmid">32296168</pub-id></mixed-citation></ref><ref id="R33"><label>33.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>ZD</given-names></name><name><surname>Wang</surname><given-names>ZY</given-names></name><name><surname>Zhang</surname><given-names>SF</given-names></name><etal/></person-group>
<article-title>Aerosol and surface distribution of severe acute respiratory syndrome coronavirus 2 in hospital Wards, Wuhan, China</article-title>. <source><italic toggle="yes">Emerg Infect Dis.</italic></source>
<year>2020</year>;<volume>26</volume>:<fpage>1583</fpage>&#x02013;<lpage>1591</lpage>.<pub-id pub-id-type="pmid">32275497</pub-id></mixed-citation></ref><ref id="R34"><label>34.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hallek</surname><given-names>M</given-names></name><name><surname>Cheson</surname><given-names>BD</given-names></name><name><surname>Catovsky</surname><given-names>D</given-names></name><etal/></person-group>
<article-title>iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL</article-title>. <source><italic toggle="yes">Blood.</italic></source>
<year>2018</year>;<volume>131</volume>:<fpage>2745</fpage>&#x02013;<lpage>2760</lpage>.<pub-id pub-id-type="pmid">29540348</pub-id></mixed-citation></ref><ref id="R35"><label>35.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eichhorst</surname><given-names>BF</given-names></name><name><surname>Fischer</surname><given-names>K</given-names></name><name><surname>Fink</surname><given-names>AM</given-names></name><etal/></person-group>
<article-title>Limited clinical relevance of imaging techniques in the follow-up of patients with advanced chronic lymphocytic leukemia: results of a meta-analysis</article-title>. <source><italic toggle="yes">Blood.</italic></source>
<year>2011</year>;<volume>117</volume>:<fpage>1817</fpage>&#x02013;<lpage>1821</lpage>.<pub-id pub-id-type="pmid">21139079</pub-id></mixed-citation></ref><ref id="R36"><label>36.</label><mixed-citation publication-type="other">Anderson R, May R. Infectious Diseases of Humans: Oxford Science Publications; 1992.</mixed-citation></ref><ref id="R37"><label>37.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van de Haar</surname><given-names>J</given-names></name><name><surname>Holes</surname><given-names>LR</given-names></name><name><surname>Coles</surname><given-names>CE</given-names></name><etal/></person-group>
<article-title>Caring for patients with cancer in the COVID-19 era</article-title>. <source><italic toggle="yes">Nat Med.</italic></source>
<year>2020</year>;<volume>26</volume>:<fpage>665</fpage>&#x02013;<lpage>671</lpage>.<pub-id pub-id-type="pmid">32405058</pub-id></mixed-citation></ref><ref id="R38"><label>38.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hanna</surname><given-names>TP</given-names></name><name><surname>Evans</surname><given-names>GA</given-names></name><name><surname>Booth</surname><given-names>CM</given-names></name><etal/></person-group>
<article-title>Cancer, COVID-19 and the precautionary principle: prioritizing treatment during a global pandemic</article-title>. <source><italic toggle="yes">Nat Rev Clin Oncol.</italic></source>
<year>2020</year>;<volume>17</volume>:<fpage>268</fpage>&#x02013;<lpage>270</lpage>.<pub-id pub-id-type="pmid">32242095</pub-id></mixed-citation></ref><ref id="R39"><label>39.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dignani</surname><given-names>MC</given-names></name><name><surname>Costantini</surname><given-names>P</given-names></name><name><surname>Salgueira</surname><given-names>C</given-names></name><etal/></person-group>
<article-title>Pandemic 2009 Influenza A (H1N1) virus infection in cancer and hematopoietic stem cell transplant recipients; a multicenter observational study</article-title>. <source><italic toggle="yes">F1000Res.</italic></source>
<year>2014</year>;<volume>3</volume>:<fpage>221</fpage>.<pub-id pub-id-type="pmid">25469231</pub-id></mixed-citation></ref><ref id="R40"><label>40.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>YM</given-names></name><name><surname>Hsu</surname><given-names>CY</given-names></name><name><surname>Lai</surname><given-names>CC</given-names></name><etal/></person-group>
<article-title>Impact of comorbidity on fatality rate of patients with middle east respiratory syndrome</article-title>. <source><italic toggle="yes">Sci Rep.</italic></source>
<year>2017</year>;<volume>7</volume>:<fpage>11307</fpage>.<pub-id pub-id-type="pmid">28900101</pub-id></mixed-citation></ref><ref id="R41"><label>41.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brenner</surname><given-names>H</given-names></name><name><surname>Gondos</surname><given-names>A</given-names></name><name><surname>Pulte</surname><given-names>D</given-names></name></person-group>
<article-title>Recent trends in long-term survival of patients with chronic myelocytic leukemia: disclosing the impact of advances in therapy on the population level</article-title>. <source><italic toggle="yes">Haematologica.</italic></source>
<year>2008</year>;<volume>93</volume>:<fpage>1544</fpage>&#x02013;<lpage>1549</lpage>.<pub-id pub-id-type="pmid">18641022</pub-id></mixed-citation></ref><ref id="R42"><label>42.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abrisqueta</surname><given-names>P</given-names></name><name><surname>Pereira</surname><given-names>A</given-names></name><name><surname>Rozman</surname><given-names>C</given-names></name><etal/></person-group>
<article-title>Improving survival in patients with chronic lymphocytic leukemia (1980&#x02013;2008): the Hospital Clinic of Barcelona experience</article-title>. <source><italic toggle="yes">Blood.</italic></source>
<year>2009</year>;<volume>114</volume>:<fpage>2044</fpage>&#x02013;<lpage>2050</lpage>.<pub-id pub-id-type="pmid">19553638</pub-id></mixed-citation></ref><ref id="R43"><label>43.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shanafelt</surname><given-names>TD</given-names></name><name><surname>Wang</surname><given-names>XV</given-names></name><name><surname>Kay</surname><given-names>NE</given-names></name><etal/></person-group>
<article-title>Ibrutinib-Rituximab or chemoimmunotherapy for chronic lymphocytic leukemia</article-title>. <source><italic toggle="yes">N Engl J Med.</italic></source>
<year>2019</year>;<volume>381</volume>:<fpage>432</fpage>&#x02013;<lpage>443</lpage>.<pub-id pub-id-type="pmid">31365801</pub-id></mixed-citation></ref><ref id="R44"><label>44.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Woyach</surname><given-names>JA</given-names></name><name><surname>Ruppert</surname><given-names>AS</given-names></name><name><surname>Heerema</surname><given-names>NA</given-names></name><etal/></person-group>
<article-title>Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL</article-title>. <source><italic toggle="yes">N Engl J Med.</italic></source>
<year>2018</year>;<volume>379</volume>:<fpage>2517</fpage>&#x02013;<lpage>2528</lpage>.<pub-id pub-id-type="pmid">30501481</pub-id></mixed-citation></ref><ref id="R45"><label>45.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moreno</surname><given-names>C</given-names></name><name><surname>Greil</surname><given-names>R</given-names></name><name><surname>Demirkan</surname><given-names>F</given-names></name><etal/></person-group>
<article-title>Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial</article-title>. <source><italic toggle="yes">Lancet Oncol.</italic></source>
<year>2019</year>;<volume>20</volume>:<fpage>43</fpage>&#x02013;<lpage>56</lpage>.<pub-id pub-id-type="pmid">30522969</pub-id></mixed-citation></ref><ref id="R46"><label>46.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kater</surname><given-names>AP</given-names></name><name><surname>Seymour</surname><given-names>JF</given-names></name><name><surname>Hillmen</surname><given-names>P</given-names></name><etal/></person-group>
<article-title>Fixed duration of venetoclax-rituximab in relapsed/refractory chronic lymphocytic leukemia eradicates minimal residual disease and prolongs survival: post-treatment follow-up of the MURANO phase III study</article-title>. <source><italic toggle="yes">J Clin Oncol.</italic></source>
<year>2019</year>;<volume>37</volume>:<fpage>269</fpage>&#x02013;<lpage>277</lpage>.<pub-id pub-id-type="pmid">30523712</pub-id></mixed-citation></ref><ref id="R47"><label>47.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burger</surname><given-names>JA</given-names></name><name><surname>Sivina</surname><given-names>M</given-names></name><name><surname>Jain</surname><given-names>N</given-names></name><etal/></person-group>
<article-title>Randomized trial of ibrutinib vs ibrutinib plus rituximab in patients with chronic lymphocytic leukemia</article-title>. <source><italic toggle="yes">Blood.</italic></source>
<year>2019</year>;<volume>133</volume>:<fpage>1011</fpage>&#x02013;<lpage>1019</lpage>.<pub-id pub-id-type="pmid">30530801</pub-id></mixed-citation></ref><ref id="R48"><label>48.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roberts</surname><given-names>AW</given-names></name><name><surname>Ma</surname><given-names>S</given-names></name><name><surname>Kipps</surname><given-names>TJ</given-names></name><etal/></person-group>
<article-title>Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables</article-title>. <source><italic toggle="yes">Blood.</italic></source>
<year>2019</year>;<volume>134</volume>:<fpage>111</fpage>&#x02013;<lpage>122</lpage>.<pub-id pub-id-type="pmid">31023700</pub-id></mixed-citation></ref><ref id="R49"><label>49.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Byrd</surname><given-names>JC</given-names></name><name><surname>Hillmen</surname><given-names>P</given-names></name><name><surname>O&#x02019;Brien</surname><given-names>S</given-names></name><etal/></person-group>
<article-title>Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab</article-title>. <source><italic toggle="yes">Blood.</italic></source>
<year>2019</year>;<volume>133</volume>:<fpage>2031</fpage>&#x02013;<lpage>2042</lpage>.<pub-id pub-id-type="pmid">30842083</pub-id></mixed-citation></ref><ref id="R50"><label>50.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Byrd</surname><given-names>JC</given-names></name><name><surname>Furman</surname><given-names>RR</given-names></name><name><surname>Coutre</surname><given-names>SE</given-names></name><etal/></person-group>
<article-title>Ibrutinib treatment for first-line and relapsed/refractory chronic lymphocytic leukemia: Final analysis of the pivotal phase 1b/2 PCYC-1102 study</article-title>. <source><italic toggle="yes">Clin Cancer Res.</italic></source>
<year>2020</year>;<comment>March 24. [Epub ahead of print]</comment>.</mixed-citation></ref><ref id="R51"><label>51.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brown</surname><given-names>JR</given-names></name><name><surname>Hillmen</surname><given-names>P</given-names></name><name><surname>O&#x02019;Brien</surname><given-names>S</given-names></name><etal/></person-group>
<article-title>Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL/SLL</article-title>. <source><italic toggle="yes">Leukemia.</italic></source>
<year>2018</year>;<volume>32</volume>:<fpage>83</fpage>&#x02013;<lpage>91</lpage>.<pub-id pub-id-type="pmid">28592889</pub-id></mixed-citation></ref><ref id="R52"><label>52.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O&#x02019;Brien</surname><given-names>S</given-names></name><name><surname>Furman</surname><given-names>RR</given-names></name><name><surname>Coutre</surname><given-names>S</given-names></name><etal/></person-group>
<article-title>Single-agent ibrutinib in treatment-naive and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience</article-title>. <source><italic toggle="yes">Blood.</italic></source>
<year>2018</year>;<volume>131</volume>:<fpage>1910</fpage>&#x02013;<lpage>1919</lpage>.<pub-id pub-id-type="pmid">29437592</pub-id></mixed-citation></ref><ref id="R53"><label>53.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Munir</surname><given-names>T</given-names></name><name><surname>Brown</surname><given-names>JR</given-names></name><name><surname>O&#x02019;Brien</surname><given-names>S</given-names></name><etal/></person-group>
<article-title>Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma</article-title>. <source><italic toggle="yes">Am J Hematol.</italic></source>
<year>2019</year>;<volume>94</volume>:<fpage>1353</fpage>&#x02013;<lpage>1363</lpage>.<pub-id pub-id-type="pmid">31512258</pub-id></mixed-citation></ref><ref id="R54"><label>54.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burger</surname><given-names>JA</given-names></name><name><surname>Barr</surname><given-names>PM</given-names></name><name><surname>Robak</surname><given-names>T</given-names></name><etal/></person-group>
<article-title>Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study</article-title>. <source><italic toggle="yes">Leukemia.</italic></source>
<year>2020</year>;<volume>34</volume>:<fpage>787</fpage>&#x02013;<lpage>798</lpage>.<pub-id pub-id-type="pmid">31628428</pub-id></mixed-citation></ref><ref id="R55"><label>55.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sharman</surname><given-names>JP</given-names></name><name><surname>Coutre</surname><given-names>SE</given-names></name><name><surname>Furman</surname><given-names>RR</given-names></name><etal/></person-group>
<article-title>Final results of a randomized, phase III Study of rituximab with or without idelalisib followed by open-label idelalisib in patients with relapsed chronic lymphocytic leukemia</article-title>. <source><italic toggle="yes">J Clin Oncol.</italic></source>
<year>2019</year>;<volume>37</volume>:<fpage>1391</fpage>&#x02013;<lpage>1402</lpage>.<pub-id pub-id-type="pmid">30995176</pub-id></mixed-citation></ref><ref id="R56"><label>56.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sharman</surname><given-names>JP</given-names></name><name><surname>Egyed</surname><given-names>M</given-names></name><name><surname>Jurczak</surname><given-names>W</given-names></name><etal/></person-group>
<article-title>Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial</article-title>. <source><italic toggle="yes">Lancet.</italic></source>
<year>2020</year>;<volume>395</volume>:<fpage>1278</fpage>&#x02013;<lpage>1291</lpage>.<pub-id pub-id-type="pmid">32305093</pub-id></mixed-citation></ref><ref id="R57"><label>57.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Flinn</surname><given-names>IW</given-names></name><name><surname>Hillmen</surname><given-names>P</given-names></name><name><surname>Montillo</surname><given-names>M</given-names></name><etal/></person-group>
<article-title>The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL</article-title>. <source><italic toggle="yes">Blood.</italic></source>
<year>2018</year>;<volume>132</volume>:<fpage>2446</fpage>&#x02013;<lpage>2455</lpage>.<pub-id pub-id-type="pmid">30287523</pub-id></mixed-citation></ref><ref id="R58"><label>58.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fischer</surname><given-names>K</given-names></name><name><surname>Al-Sawaf</surname><given-names>O</given-names></name><name><surname>Bahlo</surname><given-names>J</given-names></name><etal/></person-group>
<article-title>Venetoclax and obinutuzumab in patients with CLL and coexisting conditions</article-title>. <source><italic toggle="yes">N Engl J Med.</italic></source>
<year>2019</year>;<volume>380</volume>:<fpage>2225</fpage>&#x02013;<lpage>2236</lpage>.<pub-id pub-id-type="pmid">31166681</pub-id></mixed-citation></ref><ref id="R59"><label>59.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ghia</surname><given-names>P</given-names></name></person-group>
<article-title>Acalabrutinib vs Rituximab Plus Idelalisib (IdR) or Bendamustine (BR) by Investigator Choice in Relapsed/Refractory (RR) chronic lymphocytic leukemia: phase 3 ASCEND Study</article-title>. <source><italic toggle="yes">Hematol Oncol.</italic></source>
<year>2019</year>;<volume>37</volume>:<fpage>86</fpage>&#x02013;<lpage>87</lpage>.</mixed-citation></ref><ref id="R60"><label>60.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Byrd</surname><given-names>JC</given-names></name><name><surname>Wierda</surname><given-names>WG</given-names></name><name><surname>Schuh</surname><given-names>A</given-names></name><etal/></person-group>
<article-title>Acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia: updated phase 2 results</article-title>. <source><italic toggle="yes">Blood.</italic></source>
<year>2020</year>;<volume>135</volume>:<fpage>1204</fpage>&#x02013;<lpage>1213</lpage>.<pub-id pub-id-type="pmid">31876911</pub-id></mixed-citation></ref><ref id="R61"><label>61.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Awan</surname><given-names>FT</given-names></name><name><surname>Schuh</surname><given-names>A</given-names></name><name><surname>Brown</surname><given-names>JR</given-names></name><etal/></person-group>
<article-title>Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib</article-title>. <source><italic toggle="yes">Blood Adv.</italic></source>
<year>2019</year>;<volume>3</volume>:<fpage>1553</fpage>&#x02013;<lpage>1562</lpage>.<pub-id pub-id-type="pmid">31088809</pub-id></mixed-citation></ref><ref id="R62"><label>62.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ludwig</surname><given-names>H</given-names></name><name><surname>Muldur</surname><given-names>E</given-names></name><name><surname>Endler</surname><given-names>G</given-names></name><etal/></person-group>
<article-title>Prevalence of iron deficiency across different tumors and its association with poor performance status, disease status and anemia</article-title>. <source><italic toggle="yes">Ann Oncol.</italic></source>
<year>2013</year>;<volume>24</volume>:<fpage>1886</fpage>&#x02013;<lpage>1892</lpage>.<pub-id pub-id-type="pmid">23567147</pub-id></mixed-citation></ref><ref id="R63"><label>63.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hedenus</surname><given-names>M</given-names></name><name><surname>Karlsson</surname><given-names>T</given-names></name><name><surname>Ludwig</surname><given-names>H</given-names></name><etal/></person-group>
<article-title>Intravenous iron alone resolves anemia in patients with functional iron deficiency and lymphoid malignancies undergoing chemotherapy</article-title>. <source><italic toggle="yes">Med Oncol.</italic></source>
<year>2014</year>;<volume>31</volume>:<fpage>302</fpage>.<pub-id pub-id-type="pmid">25373320</pub-id></mixed-citation></ref><ref id="R64"><label>64.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Auyeung</surname><given-names>TW</given-names></name><name><surname>Lee</surname><given-names>JS</given-names></name><name><surname>Lai</surname><given-names>WK</given-names></name><etal/></person-group>
<article-title>The use of corticosteroid as treatment in SARS was associated with adverse outcomes: a retrospective cohort study</article-title>. <source><italic toggle="yes">J Infect.</italic></source>
<year>2005</year>;<volume>51</volume>:<fpage>98</fpage>&#x02013;<lpage>102</lpage>.<pub-id pub-id-type="pmid">16038758</pub-id></mixed-citation></ref><ref id="R65"><label>65.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>RC</given-names></name><name><surname>Tang</surname><given-names>XP</given-names></name><name><surname>Tan</surname><given-names>SY</given-names></name><etal/></person-group>
<article-title>Treatment of severe acute respiratory syndrome with glucosteroids: the Guangzhou experience</article-title>. <source><italic toggle="yes">Chest.</italic></source>
<year>2006</year>;<volume>129</volume>:<fpage>1441</fpage>&#x02013;<lpage>1452</lpage>.<pub-id pub-id-type="pmid">16778260</pub-id></mixed-citation></ref><ref id="R66"><label>66.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ho</surname><given-names>JC</given-names></name><name><surname>Ooi</surname><given-names>GC</given-names></name><name><surname>Mok</surname><given-names>TY</given-names></name><etal/></person-group>
<article-title>High-dose pulse versus nonpulse corticosteroid regimens in severe acute respiratory syndrome</article-title>. <source><italic toggle="yes">Am J Respir Crit Care Med.</italic></source>
<year>2003</year>;<volume>168</volume>:<fpage>1449</fpage>&#x02013;<lpage>1456</lpage>.<pub-id pub-id-type="pmid">12947028</pub-id></mixed-citation></ref><ref id="R67"><label>67.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arabi</surname><given-names>YM</given-names></name><name><surname>Mandourah</surname><given-names>Y</given-names></name><name><surname>Al-Hameed</surname><given-names>F</given-names></name><etal/></person-group>
<article-title>Corticosteroid therapy for Critically Ill patients with Middle East respiratory syndrome</article-title>. <source><italic toggle="yes">Am J Respir Crit Care Med.</italic></source>
<year>2018</year>;<volume>197</volume>:<fpage>757</fpage>&#x02013;<lpage>767</lpage>.<pub-id pub-id-type="pmid">29161116</pub-id></mixed-citation></ref><ref id="R68"><label>68.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>C</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Cai</surname><given-names>Y</given-names></name><etal/></person-group>
<article-title>Risk factors associated with acute respiratory distress syndrome and death in patients with Coronavirus Disease 2019 pneumonia in Wuhan, China</article-title>. <source><italic toggle="yes">JAMA Intern Med.</italic></source>
<year>2020</year>;<comment>March 13. [Epub ahead of print]</comment>.</mixed-citation></ref><ref id="R69"><label>69.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shang</surname><given-names>L</given-names></name><name><surname>Zhao</surname><given-names>J</given-names></name><name><surname>Hu</surname><given-names>Y</given-names></name><etal/></person-group>
<article-title>On the use of corticosteroids for 2019-nCoV pneumonia</article-title>. <source><italic toggle="yes">Lancet.</italic></source>
<year>2020</year>;<volume>395</volume>:<fpage>683</fpage>&#x02013;<lpage>684</lpage>.<pub-id pub-id-type="pmid">32122468</pub-id></mixed-citation></ref><ref id="R70"><label>70.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fang</surname><given-names>X</given-names></name><name><surname>Mei</surname><given-names>Q</given-names></name><name><surname>Yang</surname><given-names>T</given-names></name><etal/></person-group>
<article-title>Low-dose corticosteroid therapy does not delay viral clearance in patients with COVID-19</article-title>. <source><italic toggle="yes">J Infect.</italic></source>
<year>2020</year>;<volume>81</volume>:<fpage>147</fpage>&#x02013;<lpage>178</lpage>.</mixed-citation></ref><ref id="R71"><label>71.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Montillo</surname><given-names>M</given-names></name><name><surname>O&#x02019;Brien</surname><given-names>S</given-names></name><name><surname>Tedeschi</surname><given-names>A</given-names></name><etal/></person-group>
<article-title>Ibrutinib in previously treated chronic lymphocytic leukemia patients with autoimmune cytopenias in the RESONATE study</article-title>. <source><italic toggle="yes">Blood Cancer J.</italic></source>
<year>2017</year>;<volume>7</volume>:<fpage>e524</fpage>.<pub-id pub-id-type="pmid">28157216</pub-id></mixed-citation></ref><ref id="R72"><label>72.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Terpos</surname><given-names>E</given-names></name><name><surname>Ntanasis-Stathopoulos</surname><given-names>I</given-names></name><name><surname>Elalamy</surname><given-names>I</given-names></name><etal/></person-group>
<article-title>Hematological findings and complications of COVID-19</article-title>. <source><italic toggle="yes">Am J Hematol.</italic></source>
<year>2020</year>;<volume>95</volume>:<fpage>834</fpage>&#x02013;<lpage>847</lpage>.<pub-id pub-id-type="pmid">32282949</pub-id></mixed-citation></ref><ref id="R73"><label>73.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>X</given-names></name><name><surname>Yang</surname><given-names>Q</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><etal/></person-group>
<article-title>Thrombocytopenia and Its Association with Mortality in Patients with COVID-19</article-title>. <source><italic toggle="yes">J Thromb Haemost.</italic></source>
<year>2020</year>;<volume>18</volume>:<fpage>1469</fpage>&#x02013;<lpage>1472</lpage>.<pub-id pub-id-type="pmid">32302435</pub-id></mixed-citation></ref><ref id="R74"><label>74.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zulfiqar</surname><given-names>AA</given-names></name><name><surname>Lorenzo-Villalba</surname><given-names>N</given-names></name><name><surname>Hassler</surname><given-names>P</given-names></name><etal/></person-group>
<article-title>Immune thrombocytopenic purpura in a patient with Covid-19</article-title>. <source><italic toggle="yes">N Engl J Med.</italic></source>
<year>2020</year>;<volume>382</volume>:<fpage>e43</fpage>.<pub-id pub-id-type="pmid">32294340</pub-id></mixed-citation></ref><ref id="R75"><label>75.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Neunert</surname><given-names>C</given-names></name><name><surname>Terrell</surname><given-names>DR</given-names></name><name><surname>Arnold</surname><given-names>DM</given-names></name><etal/></person-group>
<article-title>American Society of Hematology 2019 guidelines for immune thrombocytopenia</article-title>. <source><italic toggle="yes">Blood Adv.</italic></source>
<year>2019</year>;<volume>3</volume>:<fpage>3829</fpage>&#x02013;<lpage>3866</lpage>.<pub-id pub-id-type="pmid">31794604</pub-id></mixed-citation></ref><ref id="R76"><label>76.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Visco</surname><given-names>C</given-names></name><name><surname>Rodeghiero</surname><given-names>F</given-names></name><name><surname>Romano</surname><given-names>A</given-names></name><etal/></person-group>
<article-title>Eltrombopag for immune thrombocytopenia secondary to chronic lymphoproliferative disorders: a phase 2 multicenter study</article-title>. <source><italic toggle="yes">Blood.</italic></source>
<year>2019</year>;<volume>134</volume>:<fpage>1708</fpage>&#x02013;<lpage>1711</lpage>.<pub-id pub-id-type="pmid">31570488</pub-id></mixed-citation></ref><ref id="R77"><label>77.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Connors</surname><given-names>JM</given-names></name><name><surname>Levy</surname><given-names>JH</given-names></name></person-group>
<article-title>COVID-19 and its implications for thrombosis and anticoagulation</article-title>. <source><italic toggle="yes">Blood.</italic></source>
<year>2020</year>;<volume>135</volume>:<fpage>2033</fpage>&#x02013;<lpage>2040</lpage>.<pub-id pub-id-type="pmid">32339221</pub-id></mixed-citation></ref><ref id="R78"><label>78.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mozas</surname><given-names>P</given-names></name><name><surname>Rivas-Delgado</surname><given-names>A</given-names></name><name><surname>Baumann</surname><given-names>T</given-names></name><etal/></person-group>
<article-title>Analysis of criteria for treatment initiation in patients with progressive chronic lymphocytic leukemia</article-title>. <source><italic toggle="yes">Blood Cancer J.</italic></source>
<year>2018</year>;<volume>8</volume>:<fpage>10</fpage>.<pub-id pub-id-type="pmid">29339727</pub-id></mixed-citation></ref><ref id="R79"><label>79.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davids</surname><given-names>MS</given-names></name><name><surname>Hallek</surname><given-names>M</given-names></name><name><surname>Wierda</surname><given-names>W</given-names></name><etal/></person-group>
<article-title>Comprehensive safety analysis of venetoclax monotherapy for patients with relapsed/refractory chronic lymphocytic leukemia</article-title>. <source><italic toggle="yes">Clin Cancer Res.</italic></source>
<year>2018</year>;<volume>24</volume>:<fpage>4371</fpage>&#x02013;<lpage>4379</lpage>.<pub-id pub-id-type="pmid">29895707</pub-id></mixed-citation></ref><ref id="R80"><label>80.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>C</given-names></name><name><surname>Tian</surname><given-names>X</given-names></name><name><surname>Lee</surname><given-names>YS</given-names></name><etal/></person-group>
<article-title>Partial reconstitution of humoral immunity and fewer infections in patients with chronic lymphocytic leukemia treated with ibrutinib</article-title>. <source><italic toggle="yes">Blood.</italic></source>
<year>2015</year>;<volume>126</volume>:<fpage>2213</fpage>&#x02013;<lpage>2219</lpage>.<pub-id pub-id-type="pmid">26337493</pub-id></mixed-citation></ref><ref id="R81"><label>81.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Varughese</surname><given-names>T</given-names></name><name><surname>Taur</surname><given-names>Y</given-names></name><name><surname>Cohen</surname><given-names>N</given-names></name><etal/></person-group>
<article-title>Serious infections in patients receiving ibrutinib for treatment of lymphoid cancer</article-title>. <source><italic toggle="yes">Clin Infect Dis.</italic></source>
<year>2018</year>;<volume>67</volume>:<fpage>687</fpage>&#x02013;<lpage>692</lpage>.<pub-id pub-id-type="pmid">29509845</pub-id></mixed-citation></ref><ref id="R82"><label>82.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rogers</surname><given-names>KA</given-names></name><name><surname>Mousa</surname><given-names>L</given-names></name><name><surname>Zhao</surname><given-names>Q</given-names></name><etal/></person-group>
<article-title>Incidence of opportunistic infections during ibrutinib treatment for B-cell malignancies</article-title>. <source><italic toggle="yes">Leukemia.</italic></source>
<year>2019</year>;<volume>33</volume>:<fpage>2527</fpage>&#x02013;<lpage>2530</lpage>.<pub-id pub-id-type="pmid">31086260</pub-id></mixed-citation></ref><ref id="R83"><label>83.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Weerdt</surname><given-names>I</given-names></name><name><surname>Hofland</surname><given-names>T</given-names></name><name><surname>de Boer</surname><given-names>R</given-names></name><etal/></person-group>
<article-title>Distinct immune composition in lymph node and peripheral blood of CLL patients is reshaped during venetoclax treatment</article-title>. <source><italic toggle="yes">Blood Adv.</italic></source>
<year>2019</year>;<volume>3</volume>:<fpage>2642</fpage>&#x02013;<lpage>2652</lpage>.<pub-id pub-id-type="pmid">31506282</pub-id></mixed-citation></ref><ref id="R84"><label>84.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Long</surname><given-names>M</given-names></name><name><surname>Beckwith</surname><given-names>K</given-names></name><name><surname>Do</surname><given-names>P</given-names></name><etal/></person-group>
<article-title>Ibrutinib treatment improves T cell number and function in CLL patients</article-title>. <source><italic toggle="yes">J Clin Invest.</italic></source>
<year>2017</year>;<volume>127</volume>:<fpage>3052</fpage>&#x02013;<lpage>3064</lpage>.<pub-id pub-id-type="pmid">28714866</pub-id></mixed-citation></ref><ref id="R85"><label>85.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yin</surname><given-names>Q</given-names></name><name><surname>Sivina</surname><given-names>M</given-names></name><name><surname>Robins</surname><given-names>H</given-names></name><etal/></person-group>
<article-title>Ibrutinib therapy increases T Cell repertoire diversity in patients with chronic lymphocytic leukemia</article-title>. <source><italic toggle="yes">J Immunol.</italic></source>
<year>2017</year>;<volume>198</volume>:<fpage>1740</fpage>&#x02013;<lpage>1747</lpage>.<pub-id pub-id-type="pmid">28077600</pub-id></mixed-citation></ref><ref id="R86"><label>86.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Treon</surname><given-names>SP</given-names></name><name><surname>Castillo</surname><given-names>J</given-names></name><name><surname>Skarbnik</surname><given-names>AP</given-names></name><etal/></person-group>
<article-title>The BTK-inhibitor ibrutinib may protect against pulmonary injury in COVID-19 infected patients</article-title>. <source><italic toggle="yes">Blood.</italic></source>
<year>2020</year>;<volume>135</volume>:<fpage>1912</fpage>&#x02013;<lpage>1915</lpage>.<pub-id pub-id-type="pmid">32302379</pub-id></mixed-citation></ref><ref id="R87"><label>87.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chong</surname><given-names>EA</given-names></name><name><surname>Roeker</surname><given-names>LE</given-names></name><name><surname>Shadman</surname><given-names>M</given-names></name><etal/></person-group>
<article-title>BTK inhibitors in cancer patients with COVID19: &#x0201c;The winner will be the one who controls that chaos&#x0201d; (Napoleon Bonaparte)</article-title>. <source><italic toggle="yes">Clin Cancer Res.</italic></source>
<year>2020</year>;<comment>April 28. [Epub ahead of print]</comment>.</mixed-citation></ref><ref id="R88"><label>88.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shanafelt</surname><given-names>TD</given-names></name><name><surname>Wang</surname><given-names>XV</given-names></name><name><surname>Kay</surname><given-names>NE</given-names></name><etal/></person-group>
<article-title>Ibrutinib-rituximab or chemoimmunotherapy for chronic lymphocytic leukemia</article-title>. <source><italic toggle="yes">N Engl J Med.</italic></source>
<year>2019</year>;<volume>381</volume>:<fpage>432</fpage>&#x02013;<lpage>443</lpage>.<pub-id pub-id-type="pmid">31365801</pub-id></mixed-citation></ref><ref id="R89"><label>89.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O&#x02019;Brien</surname><given-names>SM</given-names></name><name><surname>Byrd</surname><given-names>JC</given-names></name><name><surname>Hillmen</surname><given-names>P</given-names></name><etal/></person-group>
<article-title>Outcomes with ibrutinib by line of therapy and post-ibrutinib discontinuation in patients with chronic lymphocytic leukemia: phase 3 analysis</article-title>. <source><italic toggle="yes">Am J Hematol.</italic></source>
<year>2019</year>;<volume>94</volume>:<fpage>554</fpage>&#x02013;<lpage>562</lpage>.<pub-id pub-id-type="pmid">30767298</pub-id></mixed-citation></ref><ref id="R90"><label>90.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parikh</surname><given-names>SA</given-names></name><name><surname>Achenbach</surname><given-names>SJ</given-names></name><name><surname>Call</surname><given-names>TG</given-names></name><etal/></person-group>
<article-title>The impact of dose modification and temporary interruption of ibrutinib on outcomes of chronic lymphocytic leukemia patients in routine clinical practice</article-title>. <source><italic toggle="yes">Cancer Med.</italic></source>
<year>2020</year>;<volume>9</volume>:<fpage>3390</fpage>&#x02013;<lpage>3399</lpage>.<pub-id pub-id-type="pmid">32187452</pub-id></mixed-citation></ref><ref id="R91"><label>91.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dave</surname><given-names>N</given-names></name><name><surname>Gopalakrishnan</surname><given-names>S</given-names></name><name><surname>Mensing</surname><given-names>S</given-names></name><etal/></person-group>
<article-title>Model-informed dosing of venetoclax in healthy subjects: an exposure-response analysis</article-title>. <source><italic toggle="yes">Clin Transl Sci.</italic></source>
<year>2019</year>;<volume>12</volume>:<fpage>625</fpage>&#x02013;<lpage>632</lpage>.<pub-id pub-id-type="pmid">31268229</pub-id></mixed-citation></ref><ref id="R92"><label>92.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Furman</surname><given-names>RR</given-names></name><name><surname>Sharman</surname><given-names>JP</given-names></name><name><surname>Coutre</surname><given-names>SE</given-names></name><etal/></person-group>
<article-title>Idelalisib and rituximab in relapsed chronic lymphocytic leukemia</article-title>. <source><italic toggle="yes">N Engl J Med.</italic></source>
<year>2014</year>;<volume>370</volume>:<fpage>997</fpage>&#x02013;<lpage>1007</lpage>.<pub-id pub-id-type="pmid">24450857</pub-id></mixed-citation></ref><ref id="R93"><label>93.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lampson</surname><given-names>BL</given-names></name><name><surname>Kim</surname><given-names>HT</given-names></name><name><surname>Davids</surname><given-names>MS</given-names></name><etal/></person-group>
<article-title>Efficacy results of a phase 2 trial of first-line idelalisib plus ofatumumab in chronic lymphocytic leukemia</article-title>. <source><italic toggle="yes">Blood Adv.</italic></source>
<year>2019</year>;<volume>3</volume>:<fpage>1167</fpage>&#x02013;<lpage>1174</lpage>.<pub-id pub-id-type="pmid">30967392</pub-id></mixed-citation></ref><ref id="R94"><label>94.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McLaughlin</surname><given-names>P</given-names></name><name><surname>Grillo-Lopez</surname><given-names>AJ</given-names></name><name><surname>Link</surname><given-names>BK</given-names></name><etal/></person-group>
<article-title>Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program</article-title>. <source><italic toggle="yes">J Clin Oncol.</italic></source>
<year>1998</year>;<volume>16</volume>:<fpage>2825</fpage>&#x02013;<lpage>2833</lpage>.<pub-id pub-id-type="pmid">9704735</pub-id></mixed-citation></ref><ref id="R95"><label>95.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carson</surname><given-names>KR</given-names></name><name><surname>Focosi</surname><given-names>D</given-names></name><name><surname>Major</surname><given-names>EO</given-names></name><etal/></person-group>
<article-title>Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a review from the research on adverse drug events and reports (RADAR) project</article-title>. <source><italic toggle="yes">Lancet Oncol.</italic></source>
<year>2009</year>;<volume>10</volume>:<fpage>816</fpage>&#x02013;<lpage>824</lpage>.<pub-id pub-id-type="pmid">19647202</pub-id></mixed-citation></ref><ref id="R96"><label>96.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mozessohn</surname><given-names>L</given-names></name><name><surname>Chan</surname><given-names>KK</given-names></name><name><surname>Feld</surname><given-names>JJ</given-names></name><etal/></person-group>
<article-title>Hepatitis B reactivation in HBsAg-negative/HBcAb-positive patients receiving rituximab for lymphoma: a meta-analysis</article-title>. <source><italic toggle="yes">J Viral Hepat.</italic></source>
<year>2015</year>;<volume>22</volume>:<fpage>842</fpage>&#x02013;<lpage>849</lpage>.<pub-id pub-id-type="pmid">25765930</pub-id></mixed-citation></ref><ref id="R97"><label>97.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shen</surname><given-names>C</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Zhao</surname><given-names>F</given-names></name><etal/></person-group>
<article-title>Treatment of 5 critically Ill patients with COVID-19 with convalescent plasma</article-title>. <source><italic toggle="yes">JAMA.</italic></source>
<year>2020</year>;<volume>323</volume>:<fpage>1582</fpage>&#x02013;<lpage>1589</lpage>.</mixed-citation></ref><ref id="R98"><label>98.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Xu</surname><given-names>Y</given-names></name><name><surname>Gao</surname><given-names>R</given-names></name><etal/></person-group>
<article-title>Detection of SARS-CoV-2 in different types of clinical specimens</article-title>. <source><italic toggle="yes">JAMA.</italic></source>
<year>2020</year>;<volume>323</volume>:<fpage>1843</fpage>&#x02013;<lpage>1844</lpage>.</mixed-citation></ref><ref id="R99"><label>99.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zou</surname><given-names>L</given-names></name><name><surname>Ruan</surname><given-names>F</given-names></name><name><surname>Huang</surname><given-names>M</given-names></name><etal/></person-group>
<article-title>SARS-CoV-2 viral load in upper respiratory specimens of infected patients</article-title>. <source><italic toggle="yes">N Engl J Med.</italic></source>
<year>2020</year>;<volume>382</volume>:<fpage>1177</fpage>&#x02013;<lpage>1179</lpage>.<pub-id pub-id-type="pmid">32074444</pub-id></mixed-citation></ref><ref id="R100"><label>100.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wolfel</surname><given-names>R</given-names></name><name><surname>Corman</surname><given-names>VM</given-names></name><name><surname>Guggemos</surname><given-names>W</given-names></name><etal/></person-group>
<article-title>Virological assessment of hospitalized patients with COVID</article-title>. <source><italic toggle="yes">Nature.</italic></source>
<year>2020</year>;<volume>581</volume>:<fpage>465</fpage>&#x02013;<lpage>469</lpage>.<pub-id pub-id-type="pmid">32235945</pub-id></mixed-citation></ref><ref id="R101"><label>101.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Yan</surname><given-names>LM</given-names></name><name><surname>Wan</surname><given-names>L</given-names></name><etal/></person-group>
<article-title>Viral dynamics in mild and severe cases of COVID-19</article-title>. <source><italic toggle="yes">Lancet Infect Dis.</italic></source>
<year>2020</year>;<volume>20</volume>:<fpage>656</fpage>&#x02013;<lpage>657</lpage>.<pub-id pub-id-type="pmid">32199493</pub-id></mixed-citation></ref><ref id="R102"><label>102.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jin</surname><given-names>X</given-names></name><name><surname>Lian</surname><given-names>JS</given-names></name><name><surname>Hu</surname><given-names>JH</given-names></name><etal/></person-group>
<article-title>Epidemiological, clinical and virological characteristics of 74 cases of coronavirus-infected disease 2019 (COVID-19) with gastrointestinal symptoms</article-title>. <source><italic toggle="yes">Gut.</italic></source>
<year>2020</year>;<volume>69</volume>:<fpage>1002</fpage>&#x02013;<lpage>1009</lpage>.<pub-id pub-id-type="pmid">32213556</pub-id></mixed-citation></ref><ref id="R103"><label>103.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rubin</surname><given-names>GD</given-names></name><name><surname>Ryerson</surname><given-names>CJ</given-names></name><name><surname>Haramati</surname><given-names>LB</given-names></name><etal/></person-group>
<article-title>The role of chest imaging in patient management during the COVID-19 pandemic: a multinational consensus statement from the Fleischner society</article-title>. <source><italic toggle="yes">Chest.</italic></source>
<year>2020</year>;<volume>158</volume>:<fpage>106</fpage>&#x02013;<lpage>116</lpage>.<pub-id pub-id-type="pmid">32275978</pub-id></mixed-citation></ref><ref id="R104"><label>104.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chow</surname><given-names>EJ</given-names></name><name><surname>Schwartz</surname><given-names>NG</given-names></name><name><surname>Tobolowsky</surname><given-names>FA</given-names></name><etal/></person-group>
<article-title>Symptom screening at illness onset of health care personnel with SARS-CoV-2 infection in King County, Washington</article-title>. <source><italic toggle="yes">JAMA.</italic></source>
<year>2020</year>;<volume>323</volume>:<fpage>2087</fpage>&#x02013;<lpage>2089</lpage>.</mixed-citation></ref><ref id="R105"><label>105.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheung</surname><given-names>KS</given-names></name><name><surname>Hung</surname><given-names>IF</given-names></name><name><surname>Chan</surname><given-names>PP</given-names></name><etal/></person-group>
<article-title>Gastrointestinal manifestations of SARS-CoV-2 infection and virus load in fecal samples from the Hong Kong Cohort and systematic review and meta-analysis</article-title>. <source><italic toggle="yes">Gastroenterology.</italic></source>
<year>2020</year>;<comment>April 3. [Epub ahead of print]</comment>.</mixed-citation></ref><ref id="R106"><label>106.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Benezit</surname><given-names>F</given-names></name><name><surname>Le Turnier</surname><given-names>P</given-names></name><name><surname>Declerck</surname><given-names>C</given-names></name><etal/></person-group>
<article-title>Utility of hyposmia and hypogeusia for the diagnosis of COVID-19</article-title>. <source><italic toggle="yes">Lancet Infect Dis.</italic></source>
<year>2020</year>;<comment>April 15. [Epub ahead of print]</comment>.</mixed-citation></ref><ref id="R107"><label>107.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kimball</surname><given-names>A</given-names></name><name><surname>Hatfield</surname><given-names>KM</given-names></name><name><surname>Arons</surname><given-names>M</given-names></name><etal/></person-group>
<article-title>Asymptomatic and presymptomatic SARS-CoV-2 infections in residents of a long-term care Skilled Nursing Facility - King County, Washington, March 2020</article-title>. <source><italic toggle="yes">MMWR Morb Mortal Wkly Rep.</italic></source>
<year>2020</year>;<volume>69</volume>:<fpage>377</fpage>&#x02013;<lpage>381</lpage>.<pub-id pub-id-type="pmid">32240128</pub-id></mixed-citation></ref><ref id="R108"><label>108.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arons</surname><given-names>MM</given-names></name><name><surname>Hatfield</surname><given-names>KM</given-names></name><name><surname>Reddy</surname><given-names>SC</given-names></name><etal/></person-group>
<article-title>Presymptomatic SARS-CoV-2 infections and transmission in a skilled nursing facility</article-title>. <source><italic toggle="yes">N Engl J Med.</italic></source>
<year>2020</year>;<volume>382</volume>:<fpage>2081</fpage>&#x02013;<lpage>2090</lpage>.<pub-id pub-id-type="pmid">32329971</pub-id></mixed-citation></ref><ref id="R109"><label>109.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kong</surname><given-names>WH</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Peng</surname><given-names>MW</given-names></name><etal/></person-group>
<article-title>SARS-CoV-2 detection in patients with influenza-like illness</article-title>. <source><italic toggle="yes">Nat Microbiol.</italic></source>
<year>2020</year>;<volume>5</volume>:<fpage>675</fpage>&#x02013;<lpage>678</lpage>.<pub-id pub-id-type="pmid">32265517</pub-id></mixed-citation></ref><ref id="R110"><label>110.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bordi</surname><given-names>L</given-names></name><name><surname>Nicastri</surname><given-names>E</given-names></name><name><surname>Scorzolini</surname><given-names>L</given-names></name><etal/></person-group>
<article-title>Differential diagnosis of illness in patients under investigation for the novel coronavirus (SARS-CoV-2), Italy, February 2020</article-title>. <source><italic toggle="yes">Euro Surveill.</italic></source>
<year>2020</year>;<volume>25</volume>:<fpage>2000170</fpage>.</mixed-citation></ref><ref id="R111"><label>111.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chu</surname><given-names>HY</given-names></name><name><surname>Englund</surname><given-names>JA</given-names></name><name><surname>Starita</surname><given-names>LM</given-names></name><etal/></person-group>
<article-title>Early detection of Covid-19 through a citywide pandemic surveillance platform</article-title>. <source><italic toggle="yes">N Engl J Med.</italic></source>
<year>2020</year>;<comment>May 1. [Epub ahead of print]</comment>.</mixed-citation></ref><ref id="R112"><label>112.</label><mixed-citation publication-type="other">Sanit&#x000e0;. ISd. Characteristics of SARS-CoV-2 patients dying in Italy. 2020. <ext-link ext-link-type="uri" xlink:href="https://www.epicentro.iss.it/en/coronavirus/bollettino/Report-COVID-2019_20_april_2020.pdf">https://www.epicentro.iss.it/en/coronavirus/bollettino/Report-COVID-2019_20_april_2020.pdf</ext-link>. Accessed on April 30th, 2020.</mixed-citation></ref><ref id="R113"><label>113.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cox</surname><given-names>MJ</given-names></name></person-group>
<article-title>Co-infections: potentially lethal and unexplored in COVID-19</article-title>. <source><italic toggle="yes">Lancet Microbe.</italic></source>
<year>2020</year>;<comment>Published online April 24, 2020. </comment><pub-id pub-id-type="doi">10.1016/S2666-5247(20)30009-4</pub-id>.</mixed-citation></ref><ref id="R114"><label>114.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hampel</surname><given-names>PJ</given-names></name><name><surname>Ding</surname><given-names>W</given-names></name><name><surname>Call</surname><given-names>TG</given-names></name><etal/></person-group>
<article-title>Rapid disease progression following discontinuation of ibrutinib in patients with chronic lymphocytic leukemia treated in routine clinical practice</article-title>. <source><italic toggle="yes">Leuk Lymphoma.</italic></source>
<year>2019</year>;<volume>60</volume>:<fpage>2712</fpage>&#x02013;<lpage>2719</lpage>.<pub-id pub-id-type="pmid">31014142</pub-id></mixed-citation></ref><ref id="R115"><label>115.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thompson</surname><given-names>PA</given-names></name><name><surname>Peterson</surname><given-names>CB</given-names></name><name><surname>Strati</surname><given-names>P</given-names></name><etal/></person-group>
<article-title>Serial minimal residual disease (MRD) monitoring during first-line FCR treatment for CLL may direct individualized therapeutic strategies</article-title>. <source><italic toggle="yes">Leukemia.</italic></source>
<year>2018</year>;<volume>32</volume>:<fpage>2388</fpage>&#x02013;<lpage>2398</lpage>.<pub-id pub-id-type="pmid">29769624</pub-id></mixed-citation></ref><ref id="R116"><label>116.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burger</surname><given-names>JA</given-names></name><name><surname>Tedeschi</surname><given-names>A</given-names></name><name><surname>Barr</surname><given-names>PM</given-names></name><etal/></person-group>
<article-title>Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia</article-title>. <source><italic toggle="yes">N Engl J Med.</italic></source>
<year>2015</year>;<volume>373</volume>:<fpage>2425</fpage>&#x02013;<lpage>2437</lpage>.<pub-id pub-id-type="pmid">26639149</pub-id></mixed-citation></ref><ref id="R117"><label>117.</label><mixed-citation publication-type="other">World Health Organization. Clinical management of severe acute respiratory infection when COVID-19 is suspected. 2020, March 13. <ext-link ext-link-type="uri" xlink:href="https://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected">https://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected</ext-link>. Accessed April 30th, 2020.</mixed-citation></ref><ref id="R118"><label>118.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sanders</surname><given-names>JM</given-names></name><name><surname>Monogue</surname><given-names>ML</given-names></name><name><surname>Jodlowski</surname><given-names>TZ</given-names></name><etal/></person-group>
<article-title>Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review</article-title>. <source><italic toggle="yes">JAMA.</italic></source>
<year>2020</year>;<comment>April 13. [Epub ahead of print]</comment>.</mixed-citation></ref><ref id="R119"><label>119.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bhimraj</surname><given-names>A</given-names></name><name><surname>Morgan</surname><given-names>RL</given-names></name><name><surname>Shumaker</surname><given-names>AH</given-names></name><etal/></person-group>
<article-title>Infectious diseases society of america guidelines on the treatment and management of patients with COVID-19</article-title>. <source><italic toggle="yes">Clin Infect Dis.</italic></source>
<year>2020</year>;<comment>April 27. [Epub ahead of print]</comment>.</mixed-citation></ref><ref id="R120"><label>120.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morris</surname><given-names>DE</given-names></name><name><surname>Cleary</surname><given-names>DW</given-names></name><name><surname>Clarke</surname><given-names>SC</given-names></name></person-group>
<article-title>Secondary Bacterial Infections Associated with Influenza Pandemics</article-title>. <source><italic toggle="yes">Front Microbiol.</italic></source>
<year>2017</year>;<volume>8</volume>:<fpage>1041</fpage>.<pub-id pub-id-type="pmid">28690590</pub-id></mixed-citation></ref><ref id="R121"><label>121.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mikulska</surname><given-names>M</given-names></name><name><surname>Cesaro</surname><given-names>S</given-names></name><name><surname>de Lavallade</surname><given-names>H</given-names></name><etal/></person-group>
<article-title>Vaccination of patients with haematological malignancies who did not have transplantations: guidelines from the 2017 European Conference on Infections in Leukaemia (ECIL 7)</article-title>. <source><italic toggle="yes">Lancet Infect Dis.</italic></source>
<year>2019</year>;<volume>19</volume>:<fpage>e188</fpage>&#x02013;<lpage>e199</lpage>.<pub-id pub-id-type="pmid">30744964</pub-id></mixed-citation></ref><ref id="R122"><label>122.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Raanani</surname><given-names>P</given-names></name><name><surname>Gafter-Gvili</surname><given-names>A</given-names></name><name><surname>Paul</surname><given-names>M</given-names></name><etal/></person-group>
<article-title>Immunoglobulin prophylaxis in chronic lymphocytic leukemia and multiple myeloma: systematic review and meta-analysis</article-title>. <source><italic toggle="yes">Leuk Lymphoma.</italic></source>
<year>2009</year>;<volume>50</volume>:<fpage>764</fpage>&#x02013;<lpage>772</lpage>.<pub-id pub-id-type="pmid">19330654</pub-id></mixed-citation></ref><ref id="R123"><label>123.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Windegger</surname><given-names>TM</given-names></name><name><surname>Lambooy</surname><given-names>CA</given-names></name><name><surname>Hollis</surname><given-names>L</given-names></name><etal/></person-group>
<article-title>Subcutaneous immunoglobulin therapy for hypogammaglobulinemia secondary to malignancy or related drug therapy</article-title>. <source><italic toggle="yes">Transfus Med Rev.</italic></source>
<year>2017</year>;<volume>31</volume>:<fpage>45</fpage>&#x02013;<lpage>50</lpage>.<pub-id pub-id-type="pmid">27450021</pub-id></mixed-citation></ref><ref id="R124"><label>124.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alhazzani</surname><given-names>W</given-names></name><name><surname>Moller</surname><given-names>MH</given-names></name><name><surname>Arabi</surname><given-names>YM</given-names></name><etal/></person-group>
<article-title>Surviving sepsis campaign: guidelines on the management of critically Ill adults with coronavirus disease 2019 (COVID-19)</article-title>. <source><italic toggle="yes">Crit Care Med.</italic></source>
<year>2020</year>;<volume>48</volume>:<fpage>e440</fpage>&#x02013;<lpage>e469</lpage>.<pub-id pub-id-type="pmid">32224769</pub-id></mixed-citation></ref><ref id="R125"><label>125.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>F</given-names></name><name><surname>Yan</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>N</given-names></name><etal/></person-group>
<article-title>Quantitative detection and viral load analysis of SARS-CoV-2 in infected patients</article-title>. <source><italic toggle="yes">Clin Infect Dis.</italic></source>
<year>2020</year>;<fpage>ciaa345</fpage>.</mixed-citation></ref><ref id="R126"><label>126.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>To</surname><given-names>KK</given-names></name><name><surname>Tsang</surname><given-names>OT</given-names></name><name><surname>Leung</surname><given-names>WS</given-names></name><etal/></person-group>
<article-title>Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study</article-title>. <source><italic toggle="yes">Lancet Infect Dis.</italic></source>
<year>2020</year>;<volume>20</volume>:<fpage>565</fpage>&#x02013;<lpage>574</lpage>.<pub-id pub-id-type="pmid">32213337</pub-id></mixed-citation></ref><ref id="R127"><label>127.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>K</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Yuan</surname><given-names>J</given-names></name><etal/></person-group>
<article-title>Factors associated with prolonged viral RNA shedding in patients with COVID-19</article-title>. <source><italic toggle="yes">Clin Infect Dis.</italic></source>
<year>2020</year>;<fpage>ciaa351</fpage>.</mixed-citation></ref><ref id="R128"><label>128.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yuan</surname><given-names>J</given-names></name><name><surname>Kou</surname><given-names>S</given-names></name><name><surname>Liang</surname><given-names>Y</given-names></name><etal/></person-group>
<article-title>PCR assays turned positive in 25 discharged COVID-19 patients</article-title>. <source><italic toggle="yes">Clin Infect Dis.</italic></source>
<year>2020</year>;<fpage>ciaa398</fpage>.<pub-id pub-id-type="pmid">32266381</pub-id></mixed-citation></ref><ref id="R129"><label>129.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lescure</surname><given-names>FX</given-names></name><name><surname>Bouadma</surname><given-names>L</given-names></name><name><surname>Nguyen</surname><given-names>D</given-names></name><etal/></person-group>
<article-title>Clinical and virological data of the first cases of COVID-19 in Europe: a case series</article-title>. <source><italic toggle="yes">Lancet Infect Dis.</italic></source>
<year>2020</year>;<volume>20</volume>:<fpage>697</fpage>&#x02013;<lpage>706</lpage>.<pub-id pub-id-type="pmid">32224310</pub-id></mixed-citation></ref><ref id="R130"><label>130.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xiao</surname><given-names>AT</given-names></name><name><surname>Tong</surname><given-names>YX</given-names></name><name><surname>Zhang</surname><given-names>S</given-names></name></person-group>
<article-title>Profile of RT-PCR for SARS-CoV-2: a preliminary study from 56 COVID-19 patients</article-title>. <source><italic toggle="yes">Clin Infect Dis.</italic></source>
<year>2020</year>;<fpage>ciaa460</fpage>.<pub-id pub-id-type="pmid">32306036</pub-id></mixed-citation></ref></ref-list></back></article>